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ABSTRACT 
 
The Enamel matrix derivative Emdogain® (EMD) is a commercially available tissue extract 
preparation of porcine enamel origin. Studies have shown EMD to be clinically useful in promoting 
periodontal regeneration. EMD has been widely used in periodontal therapy for over ten years, but 
the mechanism of its action and the exact composition are not completely clear. EMD is 
predominantly amelogenin (>90%). However, unlike amelogenin, EMD has a number of growth 
factor-like effects and it has been shown to enhance the proliferation, migration and other cellular 
functions of periodontal ligament fibroblasts and osteoblasts. In contrast, the effects of EMD on 
epithelial cell lines and in particular on oral malignant cells have not been adequately studied. In 
addition, EMD has effects on the production of cytokines by several oral cell lines and the product 
is in constant interaction with different oral enzymes. Regardless of the various unknown properties 
of EMD, it is said to be clinically safe in regenerative procedures, also in medically compromised 
patients.   
 
The aim of the study was to examine whether gingival crevicular fluid (GCF), which contains 
several different proteolysis enzymes, could degrade EMD and alter its biological functions. In 
addition, the objective was to study the effects of EMD on carcinogenesis-related factors, in 
particular MMPs, using in vitro and in vivo models. This study also aimed to contribute to the 
understanding of the composition of EMD. 
 
GCF was capable of degrading EMD, depending on the periodontal status, with markedly more 
degradation in all states of periodontal disease compared to healthy controls. EMD was observed to 
stimulate the migration of periodontal ligament fibroblasts (PLF), whereas EMD together with GCF 
could not stimulate this proliferation. In addition, recombinant amelogenin, the main component of 
EMD, decreased the migration of PLFs. A comparison of changes induced by EMD and TGF-β1 in 
the gene profiles of carcinoma cells showed TGF-β1 to regulate a greater number of genes than 
EMD. However, both of the study reagents enhanced the expression of MMP-10 and MMP-9. 
Furthermore, EMD was found to induce several factors closely related to carcinogenesis on gene, 
protein, cell and in vivo levels. EMD enhanced the production of MMP-2, MMP-9 and MMP-10 
proteins by cultured carcinoma cells. In addition, EMD stimulated the migration and in vitro wound 
closure of carcinoma cells. EMD was also capable of promoting metastasis formation in mice. 
 
In conclusion, the diseased GCF, containing various proteases, causes degradation of EMD and 
decreased proliferation of PLFs. Thus, this in vitro study suggests that the regenerative effect of 
EMD may decrease due to proteases present in periodontal tissues during the inflammation and 
healing of the tissues in vivo. Furthermore, EMD was observed to enhance several carcinoma-
related factors and in particular the production of MMPs by benign and malignant cell lines. These 
findings suggest that the clinical safety of EMD with regard to dysplastic mucosal lesions should be 
further investigated. 
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1 INTRODUCTION 
 
Repair and regeneration of periodontal tissues are major goals in periodontal treatment. Periodontal 
regeneration is a complex multifactorial process in which molecular interactions in and between 
mesenchymal and epithelial cell lines are needed (Nyman et al 1982, Pitaru et al 1994). The 
essential stages in successful regeneration are cementogenesis, osteogenesis and assembly of 
periodontal ligaments onto the cementum. At the same time, the apical proliferation of epithelial 
cells must be arrested (Gottlow et al 1984, Ripamonti & Reddi 1997, Zeichner-David 2006). In 
1997, extracted porcine enamel matrix proteins were observed to be capable of inducing new 
cementum and bone formation in periodontal defects in monkeys (Hammarström 1997). Since then, 
this tissue extract preparation, consisting of hydrophobic enamel matrix proteins from developing 
porcine enamel, has been marketed under the commercial name of Emdogain® (EMD). Several in 
vivo studies since then have shown EMD to be clinically useful in promoting periodontal 
regeneration, including the restoration of alveolar bone, cementum and collagenous ligaments 
(Esposito et al 2004).  
 
Although EMD is at present widely used in periodontal therapy, the mechanisms of action and the 
exact composition of the product are not completely clear. The predominant compound of EMD is 
amelogenin (>90%) (Zeichner-David 2006). In spite of amelogenin not being a growth factor, EMD 
possesses several growth factor-like effects. Therefore, many attempts have been made to identify 
growth factors in EMD, without satisfying results. However, there is abundant evidence regarding 
the effects of EMD on periodontal tissues. EMD can stimulate the migration and proliferation of 
periodontal fibroblasts and osteoblasts and induce the production of several cytokines in these cells. 
In contrast to periodontal fibroblasts and osteoblasts, other cell lines of the oral cavity, particularly 
malignant cell lines, have not been adequately studied. Despite the lack of studies and the fact that 
EMD is known to have growth factor-like effects on different cell lines, EMD is said to be 
clinically safe (Zetterström et al 1997, Heard et al 2000, Oringer 2002). In studies, however, the 
clinical safety has often entailed only the capability of porcine enamel proteins to induce 
immunological reactions or local post-operative symptoms such as pain or sensitivity in the teeth 
involved. Nonetheless, EMD is applied in high doses directly in periodontal pockets where it 
interacts with proteolytic enzymes, e.g. MMPs, of inflamed tissue. Thus, this combination of 
proteolytic enzymes together with unknown cytokines of EMD might also be capable of inducing 
unwanted effects and alterations in vivo. 
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These observations led to two distinct hypothesis of the study. The first hypothesis was that the 
proteases present in oral tissues and oral fluids can degrade EMD and the degradation alters the 
effects of EMD in vitro. The Second hypothesis was that EMD could be capable of inducing 
carcinogenesis. Thus, the purpose of this study was to examine whether gingival crevicular fluid, 
containing several different proteolytic enzymes, could degrade EMD and alter the proliferation of 
periodontal fibroblasts. In addition, the study aimed to determine if EMD could induce 
carcinogenesis-related factors, in particular MMPs, in vitro and in vivo. Furthermore, this study 
aimed to contribute to the understanding of the composition of EMD.  
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2 REVIEW OF THE LITERATURE 
 
2.1 Healthy and diseased periodontium 
 
Periodontal tissue surrounding the tooth consists of four different developmental, biological and 
functional units: gingiva, root cementum, alveolar bone and periodontal ligament (Mueller 2005). 
These tissues can support and nourish the related tooth and protect underlying tissues, and thus are 
responsible for the main functions of the periodontium.  
 
 
Figure 1. The structure of the periodontium. A. corresponds to a healthy state and B. to 
periodontitis. The vertical arrows show the flow direction of the gingival crevicular fluid to the 
gingival crevice. 
 
The transition from a healthy state or gingivitis to periodontitis is characterised by proteolytic 
destruction of periodontal ligament (type I collagen fibers) and alveolar bone accompanied by 
apical migration of sulcular epithelial cells. This phenomenon leads to periodontal pocket formation 
and eventually to loss of the tooth involved. Periodontal diseases can be grouped according to the 
degree, severity and activity of the tissue destruction. In 1999, an International Workshop for the 
Classification of Periodontal Disease and Conditions was organised to revise the classification 
system of periodontal diseases (Armitage 1999). The major disease categories are: I gingival 
 10
disease, II chronic periodontitis, III aggressive periodontitis, IV periodontitis as a manifestation of 
systemic diseases, V necrotising periodontal disease, VI abscesses of the periodontium, VII 
periodontitis associated with endodontic lesions, and VIII development of acquired deformities and 
conditions.  
 
All the forms of periodontitis are first and foremost infectious diseases and initiated by bacteria. All 
of the periodontopathogens, particularly Porphyromonas gingivalis, Aggregatibacter 
actinomycetemcomitans and Treponema denticola, can produce proteolytic enzymes directly 
capable of degrading host tissues and activating host pro-MMPs (Ding et al 1995, Potempa et al 
2000, Eley & Cox 2003). However, host-derived proteolytic enzymes cause most of the tissue 
destruction in periodontitis. Lipolysaccarides produced by gram-negative bacteria stimulate 
polymorphonuclear leukocytes and macrophages to secrete inflammatory products such as 
prostaglandin E2 (PGE2), interleukin-1 (IL-1), -6 and -8, tumour necrosis factor alpha (TNFα), and 
matrix metalloproteinases (MMPs). These products in turn activate vascular smooth muscle cells, 
sulcular epithelial cells, gingival fibroblasts, polymorphonuclear leukocytes, macrophages, mast 
cells and osteoclasts to stimulate the inflammation process further by producing various proteolytic 
enzymes capable of degrading periodontal soft-tissues and alveolar bone (Birkedal-Hansen 1993, 
Sorsa et al 2004, 2006).  
 
2.2 Gingival crevicular fluid 
 
Healthy gingival crevicular fluid (GCF) is a transudate of serum origin that diffuses passively 
through the gingival tissues, BM, and epithelium to the gingival crevice (Cimosoni 1983, Curtis et 
al 1990). In a healthy gingiva, GCF is secreted only in small amounts and is rather homogenous, 
containing mainly plasma components and normal tissue turnover-related proteins (Curtis et al 
1990). Due to plague formation and bacterial accumulation around the tooth, the vascular 
permeability of gingival capillaries increases according to the level of the disease, i.e. healthy 
gingiva, gingivitis and periodontitis. As a result, the GCF changes from transudate into an 
inflammatory exudate and the volume secreted increases.  Furthermore, the protein content of GCF 
in diseased states differs significantly from that of the healthy GCF. Diseased GCF contains more 
proteolytic enzymes as well as proteins of non-plasma origin produced by the cells of the 
periodontal connective tissue and by the sulcular and attached epithelium of the gingiva (Curtis et al 
1990, Sorsa et al 2004, 2006). There are more than 65 different infection-induced enzymes found in 
GCF, including gelatinases, collagenases, cytokines and various tissue breakdown products 
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(Armitage 2004). In addition to different proteins, diseased GCF is also rich in cells, in particular 
leukocytes and microbes from the bacterial plaque (Lamster & Ahlo 2007). Regardless of the 
increased flow rate of the GCF in periodontitis, the volume alone does not necessarily reflect 
periodontal disease activity. However, the enzyme composition of GCF follows and reflects the 
progression of periodontitis and may serve as a diagnostic tool of the disease (Kinane et al 2003, 
Sorsa et al 2004, 2006, Mäntylä et al 2003, 2006). 
 
2.3 Matrix metalloproteinases 
 
Structural and functional characteristics of matrix metalloproteinases 
 
Human endopeptidases can collectively degrade all extracellular matrix (ECM) and basement 
membrane (BM) components and are pivotal to normal tissue turnover and development as well as 
to several destructive diseases, including periodontitis and carcinoma. They can be divided into five 
major classes, i.e. serine, cysteine, metallo, aspartic and thereonine proteases, based on their 
catalytic properties and inhibitor sensitivities (Stöcker & Bode 1995, Cawston & Wilson 2006, 
Lόpez-Otίn & Matrisian 2007). Matrix metalloproteinases were discovered in 1962 to be 
responsible for the observed degradation of the frog tail. Since then, 23 human matrix 
metalloproteinases (MMPs) have been found and they form a superfamily of structurally related 
zinc-dependent endopeptidases. MMPs are either secreted or cell-membrane bound, and they are 
most often classified according to their structure and substrate specificity into six subgroups: 
collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), stromelysins and stromelysin-like 
MMPs (MMP-3, -10, -11, and -12), matrilysins (MMP-7 and -26), membrane-type MMPs (MMP-
14, -15, -16, -17, - 24, and -25), and other MMPs (MMP-19, -20, -21, -23, -27, and -28) (Nagase & 
Woessner 1999, Sternlicht & Werb 2001, Nagase et al 2006). The MMP polypeptides differ in size 
(20 to 100 kDa) and contain several distinct domains, which are similar among the different 
members of the family. The basic domain structure of MMPs consist of a pre-domain, a zinc-
binding catalytic domain, and a C-terminal hemopexin domain (excluding MMP- 7 and -26), which 
is linked to the catalytic domain by a hinge region. They are, with the exception of MMP-11, 
secreted as inactive zymogens and activated outside the cell by other MMPs, serine proteases, 
microbial proteases as well as other factors such as oxygen-derived free radicals (Saari et al 1990, 
Sorsa et al 1992, Moilanen et al 2003). For their activation, proteolytic removal of the propeptide-
domain is required. This results in a reduction in the molecular weight and enables access to the 
catalytic site of the MMPs (Nagase 1997, Nagase et al 2006, Page-McCaw et al 2007). 
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MMPs act as the main processors of ECM components. As such, they participate in physiological 
processes involving ontogenesis, organ development, tissue turnover and repair. Thus, MMPs are 
centrally involved in e.g. ovulation, embryogenesis, organ morphogenesis, nerve growth, 
angiogenesis, hair follicle cycling, inflammatory cell function, apoptosis, tooth eruption, bone 
remodelling and wound healing. More recently, MMPs have also been implicated in more 
sophisticated processes than mere ECM turnover. These include the release, activation and 
modification of cell-signalling molecules and their receptors. Substrates in these processes can vary, 
and can be other proteases, protease inhibitors, clotting factors, antimicrobial peptides, growth 
factors, hormones, and cytokines (Brinckerhoff & Matrisian 2002, Egeblad & Werb 2002, Mott & 
Werb 2004, Murphy & Nagase 2008).  
 
Under physiological conditions there is a precise regulation of proteolytic degradation and 
inhibition of proteolysis. To ensure physiologically beneficial MMP activity, regulation takes place 
at all levels of protein synthesis (e.g. transcription, translation) and secretion. In addition, MMP 
activity is regulated by physiological inhibitors, i.e.TIMPs (Visse & Nagase 2003). Furthermore, 
regulatory actions are mediated by growth factors, hormones, cytokines, cell matrix, cell-cell 
interactions and cellular transformation as well as by extrinsic chemical/physical factors. 
Disturbance in this physiological balance seems to be related to several pathological conditions and 
destructive diseases, including cancer and periodontal disease, together with arthritis, 
cardiovascular disease, nephritis, neurological diseases, lung diseases, gastric ulceration, eye 
diseases, corneal ulceration, skin diseases, liver fibrosis, atherogenesis, emphysema and chronic 
wound healing (Nagase & Woessner 1999, McCawley & Matrisian 2000, Sorsa et al 2004, Nagase 
et al 2006). 
 
Gelatinases; MMP-2 and MMP-9 
 
Gelatinases (type IV collagenases) MMP-2 and MMP-9 are also called gelatinase A and gelatinase 
B, respectively, because they were first identified based on their ability to degrade gelatin. The 
structure of the two gelatinases is similar and typical for the MMPs. Both MMP-2 and MMP-9 also 
contain fibronectin type II-like repeats in their catalytic domains. Due to these repeats, the enzymes 
have largely overlapping substrate specificities and high affinities for type IV collagen, laminins 
and elastin (Van den Steen 2002, Björklund  & Koivunen 2005). In addition, gelatinases can cleave 
a number of other ECM components as well, including type II, III, V, VII and X collagens, 
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fibronectin, fibrillin and aggrecan (Birkedal-Hansen 1993, Ravanti & Kähäri 2000). However, only 
MMP-2 can degrade type I collagen (Björklund and Koivunen 2005). MMP-2 is secreted as a 72-
kDa pro-form that is cleaved into a 59-64-kDa active form (Salo et al 1983). The corresponding 
pro- and active forms of MMP-9 have masses of 92 kDa and 68-83 kDa, respectively (Birkedal-
Hansen 1993).  
 
Despite their similarities in structure and substrate profile, MMP-2 and MMP-9 are regulated quite 
differently from each other at the level of gene transcription. In general, MMP-2 is produced 
constitutively and by a wide range of cell types, i.e. dermal fibroblasts, keratinocytes, endothelial 
cells and macrophages (Frisch & Morisaki 1990, Birkedal-Hansen 1993). Expression of MMP-9 is 
normally more restricted, but inflammatory stimulation can lead to increased MMP-9 expression in 
many cell types including neutrophils, endothelial cells, alveolar cells, macrophages, fibroblasts, 
and other connective tissue cells (Vartio et al 1982, Naguse & Woessner 1999, van den Steen et al 
2002).  
 
At present, gelatinases are intensively studied, and due to their ability to degrade major BM 
components they have been found to be crucial for carcinogenesis including tongue squamous cell 
carcinomas (SCCs). Activities of these MMPs have also been found to correlate with the invasive 
potential and bad prognosis of cancer in e.g. head and neck SCCs (Salo et al 1982, Sutinen et al 
1998, Thomas et al 1999, Hong et al 2000, Ruokolainen et al 2004, de Vicente et al 2005). In 
periodontitis, particularly MMP-9 seems to be related to tissue destruction and progression of the 
disease as well as being one of the predominant MMPs present in inflamed gingival tissue, gingival 
crevicular fluid, saliva-samples and dental peri-implant sulcular fluid (Sorsa et al 2004, 2006).   
 
Stromelysins; MMP-10 
  
The stromelysin subfamily consists of stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). 
Stromelysin-3 (MMP-11) and human macrophage metalloelastase (MMP-12) are often included in 
this subgroup as being stromelysin-like MMPs (McCawley & Matrisian 2001, Visse and Nagase 
2003, Sorsa et al 2006). MMP-3 and MMP-10 are expressed in vivo by keratinocytes and fibroblasts 
as well as several malignant cell types (Birkedal-Hansen et al 1993, Giambernardi et al 1998, 
Saarialho-Kere 1998, Rechardt et al 2000). Their main substrates are basement membrane 
components such as type IV, V, IX and X collagen, fibronectin, laminin, elastin, gelatin and 
proteoglycan core proteins, but not interstitial collagens (Sorsa et al 2006). Stromelysins can also 
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activate other proMMPs. More precisely, MMP-10 activates proMMPs -1, -2, -7, -8, and -9, 
whereas MMP-3 activates proMMPs -1, -3, -7, -8, -9, and -13 (Nicholson et al 1989, Windsor et al 
1993, Knäuper et al 1996, Nakamura et al 1998, Kähäri & Saarialho-Kere 1999, McCawley & 
Matrisian 2001). Stromelysins themselves are activated by several factors including plasmin, 
kallikrein, chymase, elastase, and cathepsin G (Nagase & Woessner 1999; Lijnen 2001).  
 
Beside their physiological functions, stromelysins, like other MMPs, are related to pathological 
conditions. MMP-10 over-expression in transgenic mice leads to disorganised cell migration during 
wound healing (Krampert et al 2004). Hence, over-expression may lead to impaired wound healing, 
whereas normal regulation promotes epithelial repair. In addition, MMP-10 is also widely 
expressed in several tumours of epithelial origin, including oral carcinomas (Birkedal-Hansen et al 
2000, Impola et al 2004), where the tumour cells themselves express MMP-10, unlike several other 
MMPs that are localised predominantly in tumour stroma (Gill et al 2004). 
 
2.4 Carcinogenesis 
 
Background on oral carcinomas 
 
Head and neck squamous cell carcinomas (HNSCCs), arising from the mucosal lining of the oral 
cavity and pharynx, are currently the sixth most prevalent neoplasm in the world, with 
approximately 900 000 cases diagnosed worldwide annually (Chin et al 2006). In Finland, 481 new 
cases of HNSCCs were diagnosed in 2007. Of these, 120 were squamous cell carcinomas of the 
tongue and the prevalence of 56 new cases in women was the highest since 1961 (Finnish Cancer 
Registry). Due to the late stage of diagnosis, and to a high frequency of metastasis, recurrence and 
second primary tumours, the survival has remained poor and unchanged during the last three 
decades. In addition, HNSCC is also one the most distressing of all cancers, since extensive surgery 
is needed at the site of the most complex functional anatomy in the human body. Thus, the therapies 
often cause serious paralyses in the patient along with a need for extensive regenerative and 
rehabilitation procedures.  
 
Mechanisms of cancer growth, invasion and metastasis 
 
Tumour development and progression is a complex multistep process in which genetic errors are 
required for the first malignant cell to evolve, normally through several pre-malignant alterations. 
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This malignant cell needs to be hidden from the immune system and lose its normal proliferative 
control, and be able to divide rapidly to form tumour tissue and to invade surrounding tissues and 
eventually distant organs. Thus, several modifications in the environment that favour malignant 
progression are needed (Rusciano & Burger 1992, Fidler 1995, Hanahan & Weinberg 2000). 
 
One of the first steps towards malignancy is the epithelial to mesenchymal transition  
(EMT), resulting in free movement of the formerly tightly-bound epithelial cells. The  
ECM works as a barrier to free cell movement, and in order to migrate, cells need to activate their 
cytoskeletal motors for movement, modulate their cell-surface adhesion molecules for traction, 
cleave ECM to break the barrier and respond to chemoattractants for guidance in migration (Vu & 
Werb 2000). The next and most crucial step of carcinogenesis is the invasion through underlying 
BM, beyond which the tumour cells can spread into the adjacent connective tissue relatively freely 
(Hanahan & Weinberg 2000). In this invasion process, the proteolytic degradation of basement 
membrane and extracellular structures combined with enhanced cell motility are essential (Friedl & 
Wolf 2003). The next goal of the tumour is to form metastasis. First malignant cells penetrate 
through the walls of blood vessels or lymphatic vessels. Then, a clot of cells travels with the stream, 
attaches to the wall of a distant vessel, moves through BM and ECM and begins to grow again at 
the new site.  
 
After the initial formation, the primary tumour can reach a maximum size of only 1-2 mm without a 
blood supply. Thus, the continual growth and survival of a solid tumour requires angiogenesis. 
Angiogenesis results from hypoxia-induced expression of basic fibroblast growth factor (bFGF) and 
vascular endothelial growth factor (VEGF), growth factors that promote endothelial cell recruitment 
(Wyke 2000). Interestingly, MMPs are reported to release these factors into the tumour stroma 
(Folkman 2007). Tumour neovasculature leaks more than normal vasculature, thus it is more 
efficient in the delivery of oxygen to the tumour (Sternlicht et al 1999, Folkman 2006). 
Angiogenesis has been linked to increased metastasis formation and decreased survival of patients 
with HNSCC (Sauter et al 1999, Smith et al 2000). 
  
We have only recently started to understand the factors that affect the tumour microenvironment 
and homeostasis. Cells of SCC develop molecular strategies in order to evade the growth inhibitory 
effects of cytokines present in the tumour microenvironment. Therefore, the malignant 
transformation process is strongly associated with an altered response to cytokine stimulation 
(Douglas et al 2004). A tumour induces or spontaneously produces several immune suppressive 
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mediators causing immune dysfunctions (Chin et al 2004). Human HNSCC cells have been shown 
to secrete high levels of numerous cytokines involved in indirect modulation mechanisms of 
immune responses and proangiogenic processes (Pries et al 2006). Interestingly, the stroma 
surrounding the tumour can also participate in carcinogenesis. Stromal fibroblasts and inflammatory 
cells can cause tumorigenic conversion of epithelial cells. In addition, stromal cells can participate 
in the proteolysis of ECM and BM by producing proteolytic enzymes, including MMPs. 
Furthermore, stroma can already support and promote angiogenesis when the BM is still intact 
(Hanahan & Folkman 1996, Westermarck & Kähäri 1999, Stetler-Stevenson & Yu 2001, Friedl & 
Wolf 2003).  
  
MMPs -2, -9 and -10 in carcinogenesis 
 
A large variety of different proteases have been found to be associated with cancer progression but 
MMPs are considered to be particularly crucial in this process (McCawley & Matrisian 2000, 
Björklund & Koivunen 2005). Co-expression of several members of the MMP family is 
characteristic of human malignant tumours (van Kempen et al 2002). Elevated MMP expression has 
been found to be related to tumour invasion properties and patient prognosis. Classical MMPs have 
an important role at all stages of tumorigenesis: they enhance tumour-induced angiogenesis, release 
growth factors from the matrix or cleave their receptors, regulate apoptosis, and break down ECM 
and BM to allow tumour cell invasion and metastatic spread (McCawley & Matrisian 2000, Liotta 
& Kohn 2001, Stetler-Stevenson & Yu 2001). Paradoxically, and depending on cancer type, several 
MMPs (MMPs-3, -7, - 9, and -12) can also possess anti-cancer effects by acting as anti-
inflammatory or tumour suppressor agents or by releasing angiogenic inhibitors, such as angiostatin 
and endostatin (Cornelius et al 1998, Nyberg et al 2003, 2008). During carcinogenesis, MMPs are 
produced by malignant cells, but in many cases the greater portion of MMPs are actually secreted 
by stromal cells. For example, gelatinases (MMP-2 and MMP-9) are produced in vitro by neoplastic 
keratinocytes (Lyons et al 1991, Salo et al 1991). However, it is assumed that in vivo MMP-2 is 
produced mainly by stromal fibroblasts, whereas MMP-9 is produced both by stromal and 
carcinoma cells (Impola et al 2004, Graesslin et al 2006). Thus, the processes leading to MMP 
production, proteolysis and tumour growth are dependent on interactions in and between stromal 
and malignant cells, and these actions are probably precisely controlled and highly organised.  
 
The high ability of gelatinases (MMP-2 and MMP-9) to destroy BM (type IV collagen) and ECM 
structures may explain why they are often associated with tumour progression and with metastatic 
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formation of several carcinomas and in particular HNSCCs (Hong et al 2000, Franchi et al 2002, de 
Vicente et al 2005, Björklund & Koivunen 2005). In addition to BM and ECM degradation and 
metastasis, gelatinases take part in neoangiogenesis. MMP-9 seems to be especially associated with 
tumour vascularisation, since MMP-9 deficient mice have been shown to fail to grow 
neovasculature, whereas this ability was regained after transplantation of MMP-9 producing wild-
type stroma (Ahn & Brown 2008). Furthermore, MMP-2 and MMP-9 have been found to be up-
regulated in angiogenic lesions and to up-regulate the release of VEGF, which is a major promoter 
of angiogenesis (Bergers et al 2000, Giraudo 2004, van Hinsbergh & Koolwijk 2008). In contrast to 
these observations, MMP-9 has also been found to be able to release angiostatin from the carcinoma 
stroma, resulting in diminished neovascularisation (Bendrik et al 2008). Thus, the roles of 
gelatinases in neoangiogenesis are dual and at present not completely clear. Gelatinases can also 
regulate inflammatory reactions and apoptosis in carcinomas (Wielockx et al 2001). MMP-9 can 
suppress the proliferation of T lymphocytes by cleaving the interleukin-2a receptor, and regulate 
immune reactions by activating TGF-β and by cleaving intercellular adhesion molecule 1 (ICAM-
1), making tumour cells resistant to natural killer cell-mediated cytotoxicity (Sheu et al 2001, Fiore 
et al 2002). On the other hand, MMP-2 is able to proteolytically process monocyte chemoattractant 
proteins and suppress inflammation in vivo (McQuibban et al 2002). Clinically, MMP-2 and MMP-
9 are associated with aggressive forms of head and neck cancers with poor prognosis (Sutinen et al 
1998, Ruokolainen et al 2004, 2006, de Vicente et al 2005). In a recent meta-analysis, the relative 
risk for progression of MMP-9 positive cases from oral dysplasia to cancer was 19.00, whereas the 
relative risk factor for MMP-2 was 2.9 and considered insignificant by the authors (Smith et al 
2009).  
 
Unlike several other MMPs that are predominantly produced by tumour stroma, MMP-10 is 
expressed by malignant cells themselves (Nakamura et al 1998, Kerkelä et al 2001). MMP-10 is 
over-expressed in several human tumours of epithelial origin, including gastric cancer (Aung et al 
2006), esophageal carcinoma (Mathew et al 2002), lung carcinoma (Gill et al 2004), skin carcinoma 
(Kerkelä et al 2001) and bladder transitional cell carcinoma (Seargent et al 2005). In oral 
carcinomas, MMP-10 is widely expressed but rarely in adjacent oral tissues (Nakamura et al 1998, 
Birkedal-Hansen et al 2000). The expression profile of MMP-10 in several human tumours, coupled 
with broad substrate specificity and expression in several stages of the tumorigenic process, 
suggests that MMP-10 could be a potential tumour marker and a predictor of clinical behaviour 
(Duffy et al 2000, Kerkelä et al 2001, Vihinen et al 2002, Gill et al 2004). 
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TGF-β in carcinogenesis 
 
In humans, TGF-β has been identified in three different isoforms, TGF-β1, -β2 and -β3. Of these, 
TGF-β1 is the most abundant in most tissues including epithelium. It is a key regulator of epithelial 
homeostasis and also acts as one of the major cytokines in carcinogenesis (Derynck et al 2001, 
Prime et al 2004, Rosenthal et al 2004). TGF-β is released by tumour cells in an inactive latent 
form, which in turn can be activated by several factors including MMP-2 and MMP-9 (Yu & 
Stamenkovic 2000, Jenkins 2008). During tumour development, TGF-β has a dual role. At the early 
stage of carcinogenesis or in benign tissues it is a potent tumour suppressor and inhibits cell growth. 
However, once tumorigenesis is in later stages, TGF-β stimulates cell growth, angiogenesis, 
invasion and metastasis, including in head and neck squamous cell carcinomas (HNSCC) (Derynck 
et al 2001, Akhurst et al 2001). Whereas MMPs-2 and -9 are capable of activating TGF-β, TGF-β 
can in turn induce expression of several MMPs in carcinoma and endothelial cells, including MMP-
1, -2, -9 and -10 (Salo et al 1994, Johansson et al 2000, Wilkins-Port & Higgins 2007, Sinpitaksakul 
et al 2008). Furthermore, TGF-β can induce epithelial to mesenchymal transition in squamous cell 
carcinomas, resulting in fibroblastoid or ‘spindle-cell’ tumours having highly malignant and 
invasive properties (Derynck et al 2001). The mechanisms of angiogenesis stimulation by TGF-β 
presumably combine direct and indirect effects. TGF-β induces expression of VEGF, which in turn 
stimulates angiogenesis (Pertovaara et al 1994). TGF-β can also directly induce capillary formation 
of endothelial cells cultured on a collagen matrix (Madri et al 1988). Taken together, this 
information suggest that TGF-β is one of the major factors in carcinogenesis and correlates with 
invasive phenophypes of carcinomas (Cui et al 1996, Hagedorn et al 1999, Pasini et al 2001). 
 
2.5 Emdogain 
 
Composition of Emdogain 
 
Findings showing that enamel matrix proteins (EMPs) are expressed along the forming root 
suggested that EMPs may have a pivotal role in the differentiation of progenitor cells into 
cementoblasts (Slavkin 1989). In 1997, it was discovered that the extracted porcine enamel matrix 
proteins could actually induce new cementum and bone formation in periodontal defects in 
monkeys (Hammarström et al 1997). Since then, this tissue extract preparation of porcine origin has 
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been marketed under the brand name of Emdogain® (EMD). Commercial Emdogain consist of 
enamel matrix derivate, water, and a carrier, i.e. propylene glycol alginate (Bosshardt 2008). The 
exact composition of enamel matrix derivative is not completely clear but it contains, at least in 
part, the same proteins as those secreted by Hertwig’s epithelial cells. Thus, amelogenin is the main 
protein in EMD, constituting over 90% of the product. In addition, EMD contains non-amelogenin 
proteins including enamelin, tufelin and ameloblastin (Zeichner-David 2001, 2006). EMD has been 
found to be more effective than amelogenin in enhancing fibroblast proliferation together with other 
cellular functions (Hoang et al 2002, Chong et al 2006). Therefore, it is generally assumed that 
EMD also contains other biologically active factors beside enamel proteins (Suzuki et al 2005, 
Chong et al 2006). Kawase et al (2001, 2002) and later Suzuki et al (2005) detected TGF-β1- or 
TGF-β-like substances in EMD, and suggested that they are the main functional components of the 
product. In addition, EMD has been documented to contain a BMP-like growth factor, which 
belongs to the TGF-β family, and also BSP-like molecules (Iwata et al 2002, Suzuki et al 2005). 
However, contradictory results have also been obtained. Therefore, the cytokine content of EMD 
has not been confirmed and warrants further study (Gestrelius et al 1997). 
 
Clinically, EMD is widely used for periodontal regeneration of a teeth affected by periodontitis. 
Experimentally, EMD has also been used for tooth replantation, dentin repair, tooth movement and 
skin wound healing. Despite extensive use and numerous studies, a recent Cochrane review 
suggests that the overall treatment effect of EMD might be overestimated and the actual clinical 
advantages of the product are unknown (Esposito et al 2005). 
 
2.6 Effects of Emdogain on mesenchymal cells 
 
Emdogain and bone-derived cells 
 
Alveolar bone cells, e.g. osteoblasts, osteoclasts and their precursors, are crucial in periodontal 
regeneration. During the development of the periodontium, dental follicle cells can differentiate into 
periodontal ligament fibroblasts, cementoblasts and osteoblasts (Slavkin et al 1989, Hammarström 
et al 1997, Spahr et al 1999, Hakki et al 2001, Zeichner- David 2001). EMD has been shown to be 
capable of stimulating the proliferation of follicle cells (Hakki et al 2001).  In osteoblastogenesis, 
EMD has been shown to promote osteogenic differentiation of pluripotential mesenchymal cell 
lines into the osteoblast and/or chondroblast lineage and to stimulate transcription factors related to 
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osteogenesis and chondrogenesis (Ohyama et al 2002, Narukawa et al 2007). Furthermore, EMD 
enhances the proliferation and osteogenic potential of bone marrow stromal cells (BMSCs) (Keila et 
al 2004, Guida et al 2007). In addition, EMD has been observed to increase the ability of BMSCs’ 
to differentiate into cementoblasts (Song et al 2007). In contrast, EMD has been observed to have 
no effect on cell growth and differentiation of rat bone marrow cells (Gurpinar et al 2003, van den 
Dolder et al 2006).  
 
The studies have concluded that EMD stimulates growth, proliferation and mobility of mature 
osteoblastic cell lines and cementoblasts and regulates their gene expression (Tokiyasu et al 2000, 
Jiang et al 2001, He et al 2004, Schwarz et al 2004, Shimizu et al 2004, Galli et al 2006, Carinci et 
al 2006, Klein et al 2006, Jiang et al 2006). EMD enhances the differentiation of the osteoblasts and 
the expression of phenotype markers by increasing the production of BSP, cellular alkaline 
phosphatase (ALP) and osteocalcin (Tokiyasu et al 2000, Schwartz et al 2000, Hägewald et al 2004, 
Shimizu et al 2004, Galli et al 2006). These observations suggest that EMD stimulates proliferation 
at an early stage of osteoblastic maturation and enhances differentiation in later stages of cell 
development.  
 
EMD also has effects on cytokines produced by osteoblasts. EMD has been observed to stimulate 
TGF-β1, connective tissue growth factor (CTGF) and fibroblast growth factor (FGF-2) expression 
in human osteoblastic cells (Schwartz et al 2000, Mizutani et al 2003, Heng et al 2007). In addition, 
increased COX-2 and decreased MMP-1 expression have been demonstrated (Mizutani et al 2003). 
Both EMD and TGF-β1 can protect osteoblasts from inflammation-induced apoptosis (He et al 
2005). In the endochondral pathway, EMD can stimulate chondrocyte proliferation in addition to 
chondrogenic differentiation (Dean et al 2002, Narukawa et al 2007).  
 
EMD has partly contrasting effects on bone resorption. The receptor activator of NF-kB ligand 
(RANKL) is expressed on the surface of osteoblasts. RANKL’s binding to RANK-receptor on 
osteoclast progenitor cells leads to osteoclast differentiation. EMD can reduce the RANKL release 
by osteoblasts and enhance the production of osteoblastic osteoprotegerin (OPG), thus inhibiting the 
formation and functions of osteoclasts (He et al 2004, Galli et al 2006). Furthermore, the RANKL 
mRNA levels of periodontal ligament fibroblast are significantly down-regulated by EMD 
(Takayanagi et al 2006). However, it has also been shown that EMD induces osteoclast formation 
by interacting with and stimulating the RANKL expressed by osteoblastic cells (Otsuka et al 2005, 
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Itoh et al 2006). In conclusion, EMD may be capable of creating favourable circumstances for bone 
regeneration, since it has effects on both bone formation and resorption. Depending on the cell 
maturation, EMD can enhance the differentiation of mesenchymal cells into hard tissue-forming 
cells and promote their proliferation and growth.  
 
Emdogain and fibroblasts 
 
Several studies have confirmed that EMD enhances the proliferation, migration and in vitro wound 
healing of periodontal ligament fibroblasts and gingival fibroblasts (Gestrelius et al 1997, 
Lyngstadaas et al 2001, Rincon et al 2003, Cattaneo et al 2003, Davenport et al 2003, Okubo et al 
2003, Palioto et al 2004, Keila et al 2004, Rodrigues et al 2007, Zeldich et al 2007). The mitogenic 
signalling pathway in which EMD affects PLFs is associated with rapid phosphorylation of the 
MAP kinase family and activation of EMD-specific receptor tyrosine kinase (RTK) and 
extracellular signal-regulated kinase (ERK) (Kawase et al 2001, Matsuda et al 2002). In addition, 
EMD can inhibit gingival fibroblast caspase activation and thereby inhibit TNF-α-induced 
apoptosis and enhance survival (Zeldich et al 2007). EMD induces matrix and total protein 
synthesis (Gestrelius et al 1997, Haase & Bartold et al 2001, Rodrigues et al 2007). Furthermore, 
EMD stimulates insulin-like growth factor (IGF-I), transforming growth factor-β1 (TGF-β1), 
platelet-derived growth factor (PDGF) and interleukin-6 (IL-6) production in PLFs (Lyngstadaas et 
al 2001, Okubo et al 2003). EMD can increase the production of MMP-2 by PLFs more than 
threefold (Mirastschijski et al 2004). In angiogenesis, EMD enhances VEGF release by PLFs 
(Mirastschijski et al 2004, Schlueter et al 2007). EMD also has profound effects at the gene level. 
EMD can down-regulate genes involved in the early inflammatory phase of wound healing, while 
simultaneously up-regulating growth and repair related genes (Parkar et al 2004).  
 
The results from studies on the effects of EMD on the differentiation of fibroblasts are somewhat 
contradictory. EMD has been observed to both decrease and increase the ALP activity of PLFs 
(Okubo et al 2003, Cattaneo et al 2003, Nagano et al 2004, Rodrigues et al 2007, Lossdörfer et al 
2007). In addition, EMD can promote bone-like nodule formation but does not induce osteoblastic 
differentiation of PLFs or gingival fibroblasts (Gestrelius et al 1997, Okubo et al 2003, Keila et al 
2004, Rodrigues et al 2007). EMD can stimulate differentiation, mineralised tissue formation and 
bone metabolism by increasing and modulating OPG and RANKL expression in fibroblasts 
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(Takayanagi et al 2006, Lossdörfer et al 2007). Furthermore, EMD alters phenotype markers of 
PLFs when cultured on dental materials (Inoue et al 2004).  
 
2.7 Effects of Emdogain on epithelial cells 
 
There have only been a few studies concerning the effects of EMD on epithelial cell. During 
periodontal development, molecules from Hertwig’s epithelial root sheath can induce differentiation 
of mesenchymal precursors to form periodontal tissues. It is assumed that EMD can mimic this 
process (Slavkin et al 1989, Hammarström et al 1997, Spahr et al 1999, Hakki et al 2001, Zeichner-
David 2001, Gestrelius et al 2004). The proliferation of epithelial cell rests of Malassez (ERM) is 
enhanced by EMD (Rincon et al 2005). In addition, EMD can stimulate the expression of 
osteopontin by ERM (Rincon et al 2005). In contrast, EMD has no effect on the proliferation of rat 
tongue epithelial cells (Gestrelius et al 1997). In vivo, EMD can enhance wound epithelialisation in 
rabbits (Mirastschijski et al 2004).  
 
Evidence on the effect of EMD on endothelial cell proliferation is scarce and somewhat 
inconsistent. EMD has been demonstrated to either stimulate or to have no effects on the 
proliferation of endothelial cells (Yuan et al 2003, Schlueter et al 2007). Both of these studies have 
confirmed that EMD increases the chemotaxis of endothelial cells (Yuan et al 2003, Schlueter et al 
2007). In vivo mice experiment showed significantly more blood vessels surrounding EMD-treated 
collagen implants than controls (Yuan et al 2003). In addition, EMD has been shown to stimulate 
the production of MMP-2 by endothelial cells more than threefold (Mirastschijski et al 2004).  
 
2.8 Effects of Emdogain on neoplastic cells 
 
The effects of EMD on malignant cells have been only sparsely studied. Furthermore, most of these 
few experiments have been carried out with cells originating outside oral tissues. Thus, these 
experiments are not of particular relevance in the context of EMD and oral cancer. These studies 
conclude that EMD has either no effects or has an inhibitory effect on the proliferation of malignant 
cell lines. No differences in the proliferation of fibrosarcoma HT-1080 cells or breast cancer-
derived MCF-7 cells have been observed after EMD treatment (Gestrelius et al 1997, Takayama et 
al 2005). EMD decreases the proliferation of human cervix-derived epithelial HeLa cells, human 
osteosarcoma MG-63 cells and human squamous cell carcinoma-derived SCC-25 cells (Kawase et 
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al 2000, Schwartz et al 2000, Lyngstadaas et al 2001). It has also been shown that EMD can arrest 
the cell cycle of SCC-25 cells at G1 and do not increase SCC-25 apoptosis (Kawase et al 2000).  
 
Although it has negligible or inhibitory effects on the proliferation of malignant cells, EMD alters 
many other cellular functions. A recent study has shown EMD to be capable of enhancing the in 
vitro degradation of type I collagen by malignant MG-63 osteosarcoma cells. In addition, EMD was 
observed to stimulate the production of MMP-1, but had no effect on the production of MMP-2, -8, 
-13, or -14 (Goda et al 2008). Another study using the same MG-63 cells observed that EMD 
enhanced in vitro wound fill rates (Hoang et al 2000). However, EMD can inhibit the adhesion of 
breast cancer (MCF-7) cells to the bone matrix, but it was concluded that EMD contains BSP-like 
molecules (Takayama et al 2005). EMD increases intracellular cAMP levels and PDGF-AB 
production of HeLa cells, and the level of TGF-β1 in the culture medium of MG-63 osteosarcoma 
cells (Schwartz et al 2000, Lyngstadaas et al 2001). EMD as well as TGF-β1 stimulates 
phosphorylation of several MAP family kinases in SCC-25 cells (Kawase et al 2001, 2002).  
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3 A CASE REPORT 
 
A 63-year-old patient was referred to the Institute of Dentistry, Oulu University Central Hospital, 
Oulu, Finland by a general dental practitioner for the management of lichenoid mucosal lesions and 
periodontal disease. The patient was considered healthy with no obvious risk factors. He had no 
medication and was a non-smoker. A clinical examination revealed an almost full dentition with 
chronic periodontal disease. Probing depths of 4-5 mm were observed throughout the mouth and 
10-12 mm at the buccal aspect of d.12. Radiographs revealed alveolar bone loss distal to d.12 but 
no periapical pathology. Ulcerative and reticular lichenoid lesions were localised mostly at the 
anterior maxillary gingiva and sulcus but also at the distal aspects of the lower molars. Toluidine 
blue stained small spots at the buccal mucosa and sulcus of dd.11-12 and anterior maxillary gingiva. 
Incision biopsy from the stained regions was performed and the histological findings confirmed 
moderate dysplasia and the mucosal lesions were diagnosed clinically as non-homogenous 
leukoplakia. 
 
 
Figure 2. Prior to treatment, the gingival recession at d.12 and lichenoid lesions on the anterior 
maxilla are visible. 
 
 
Figure 3. Periapical radiograph shows alveolar bone loss around and distal to d.12. 
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The periodontal treatment proceeded as planned with an infection control phase by a course of non-
surgical root surface debridement and oral hygiene instructions. A persisting pocket at the 
distobuccal aspect of d.12 was surgically managed with EMD. Under local anaesthesia, labial and 
palatal full-thickness mucoperiosteal flaps were raised at the region dd. 11-13. The papillary tissue 
was preserved to facilitate primary closure and healing. Alveolar bone loss at buccal aspects of dd. 
11 - 13 and two-to-three wall defect at the distal aspect extending to the apical third of d.12 were 
observed. The defect was mechanically cleaned and prepared for EMD application. The root 
surfaces were rinsed with saline, conditioned for three minutes with EDTA and the Emdogain-gel® 
applied. The flaps were replaced and sutured. Post-operative instructions included rinsing the area 
with 0.2% Corsodyl® for one minute twice a day, and avoiding brushing the area and hard food. 
The surgical area was examined after one week and it was observed to be normal with no signs of 
infection or other abnormalities. The sutures were removed two weeks post-operative and the area 
was normal with minor swelling at the labial aspect.   
 
A month post-operative the area of the surgery was considered normal but the mucosa was 
thickened. Candida was diagnosed by Oricult® culture and treated with Daktarin® gel. After two 
weeks of treatment the mucosa was subjectively thinner and less uncomfortable. A culture 
confirmed the absence of Candida. At the same time, six weeks post-operative, the Corsodyl rinses 
were stopped, plaque control performed, and home care instructions repeated. Furthermore, the 
treatment of the leukoplakia was started with Bemetson® cortisone cream, applied to custom-made 
trays.   
 
After two weeks of cortisone treatment there was no improvement. The medication was continued 
for 6 weeks but the response to the treatment was poor. The white mucous lesions with some 
ulcerous red areas were spreading. Some plaque was observed but Candida was absent. To rule out 
the possibility of allergy interference, the patient was also referred for an allergy test concerning 
dental materials. Toluidine blue staining was performed and biopsy samples taken from the stained 
regions at the distobuccal aspect of d.12.   
 
The diagnosis from the area was squamous cell carcinoma, exactly four months after the EMD 
operation. Three weeks later the carcinoma was operated on. Block resection of anterior alveolar 
maxilla from d.11 to d.16 together with the floor of the maxillary sinus was performed. No 
metastasis was observed and the margins of the block were free. The partial resection was replaced 
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by a temporary prosthesis and post-operative healing was generally good. Few lichenoid lesions 
remained at dorsal aspects of the right maxilla. The lichenoid lesions at the right tuber and also at 
the regions of dd. 24 and 37 were later excised with a CO2-laser and no signs of malignancy were 
diagnosed.  
 
 
Figure 4. Clinical appearance of the anterior maxilla shortly after the resection. 
 
After the operations the patient was examined frequently and prosthetic rehabilitation was planned. 
One year after the carcinoma resection the patient observed a knot on the anterior maxilla at the 
region of d.11. The knot was clinically observed to be verrucosus leukoplakia and the alteration was 
excised. The diagnosis was moderate dysplasia. Extended surgery seemed unnecessary. Tree and a 
half years later a verrucosus leukoplakia appeared at the buccal region of d.47. Also, gingival 
pockets of 5-6 mm were observed buccal to d. 47. The tooth was extracted and a biopsy taken from 
surrounding mucosa. The diagnosis was again squamous cell carcinoma, gradus I. Part of the 
mandibular bone together with dd. 45, 46 and surrounding mucosa was resected with margins. Two 
weeks later the healing was good with little pain and no signs of inflammation. At present, the 
patient manages with an upper acrylic partial prosthesis and is re-examined frequently.      
 
In conclusion, the management of lichenoid mucosal lesions and periodontal disease were the aims 
of the treatment. Despite the dysplastic lesions, the treatment focused firstly on the periodontal 
therapy, and the regenerative surgery was performed in an area with erosive and dysplastic lesions. 
A periodontal flap surgery is highly aggravating to tissues as such, and the treatment accompanied 
by any regenerative product causes severe irritation to the inflamed tissues. Thus, this treatment was 
not a standard procedure and not according to the standard of care. Due to its several limitations, 
this case cannot prove the causal role of Emdogain-treatment on the development of oral dysplastic 
changes or carcinoma. However, this clinical observation led to the initial hypothesis of the study, 
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i.e. whether EMD could have effects on dysplastic cells in vitro? In addition, this case report also 
emphasises the importance of critical evaluation of treatments and treatment protocols as well as the 
significance of clinical observations as potential triggers also for in vitro studies.     
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4 HYPOTHESES AND AIMS OF THE STUDY 
 
EMD is currently widely used for treating patients with periodontal disease. The product is said to 
be safe with very few systemic or local contraindications (www.straumann.com). However, the 
mechanisms of actions and the exact composition of EMD are not completely clear. It has been 
shown that EMD can promote regeneration in vivo and the proliferation and growth of several 
different cell lines in vitro thus possessing growth factor-like effects. Clinically, EMD is surgically 
applied in periodontal pockets where it interacts with proteolytic enzymes, e.g. MMPs, of the 
periodontitis affected tissues. Thus, this combination of proteolytic enzymes together with unknown 
cytokines of EMD might also be capable of inducing unwanted effects and alterations in vivo. 
However, there have been no studies focusing on the associations between EMD and oral dysplasia 
or oral proteolytic enzymes. This lack of essential knowledge, which has also clinical relevance, led 
to two distinct study hypotheses. The first hypothesis was that the proteases present in oral tissues 
and oral fluids can degrade EMD, and the degradation alters the effects of EMD in vitro. The 
second hypothesis was that EMD could be capable of inducing carcinogenesis-related factors in 
vitro and in vivo. Thus, these hypotheses raised the following aims for each of the four sub-studies: 
 
I. To study the effects of GCF and MMPs on the degradation of EMD. Furthermore, the effects 
of GCF-degraded EMD on the proliferation of periodontal ligament fibroblasts were to be 
studied and compared to the effects caused by amelogenin. 
II. To examine the effects of EMD on migration, proliferation, wound closure, apoptosis, 
attachment and gelatinases (MMP-2 and -9) production of highly malignant oral tongue 
carcinoma (HSC-3) cells in vitro. In addition, the in vivo effects of EMD on HSC-3 inoculated 
mice survival and metastasis were to be studied. 
III. To compare the effects of EMD and TGF-β1 on gene expression of HSC-3 cells. In addition, 
the study aimed to contribute to the understanding of the composition of EMD by comparing 
the effects of EMD and TGF-β1.   
IV. To investigate the in vitro effects of EMD on oral tissues and carcinogenesis-related factors 
and cytokines by using a systematic literature review.  
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5 MATERIALS AND METHODS 
 
The methods used are described in detail in the original publications and briefly summarised below.   
 
5.1 Patients and sample collection (I) 
 
This study was approved by the Ethics Committee of the Ege University, Izmir, Turkey, and 
informed consent, in line with the Helsinki declaration, was obtained from each subject. A total of 
80 subjects (35 male, 45 female) were obtained from the Department of Periodontology, School of 
Dentistry, Ege University, İzmir, Turkey. The periodontal status of the subjects was determined 
according to the clinical and radiographic criteria proposed by the 1999 International World 
Workshop (Armitage, 1999). Thus, there were 20 subjects in each of the four intended study groups 
i.e. healthy subjects, subjects with gingivitis, subjects with chronic periodontitis and subjects with 
acute periodontitis  
 
A total of 156 GCF samples were collected from the subjects, with 39 samples from each group 
(healthy, gingivitis, chronic periodontitis and acute periodontitis). Prior to GCF sampling, 
supragingival plaque was removed and the surfaces were gently air-dried and isolated with cotton 
rolls. GCF samples were collected by inserting filter paper strips into gingival pockets (Periopaper, 
ProFlow, Inc., Amityville, NY, USA) for 30 seconds. During this process, care was taken to avoid 
mechanical injury, and strips contaminated with blood were discarded. GCF volume was estimated 
(Periotron 8000, ProFlow, Inc., Amityville, NY, USA) and strips were placed into a sterile 
polypropylene tube prior to freezing at -40°C. The study groups were blinded from the authors who 
conducted the in vitro assays. 
 
5.2 Study reagents (I, II, III) 
 
Lyophilised Emdogain® was provided by the manufacturer (Straumann, Basel, Switzerland. 
Previously: Biora AB, Malmö, Sweden). The EMD concentrations of 10, 100 and 200 µg/ml used 
were selected according to preliminary proliferation and gelatin zymography assays, in which the 
effects of EMD at the concentration of 0-400 µg/ml on HSC-3 carcinoma cells were tested (un-
published data not shown). 100 µg/ml was observed to be the lowest concentration giving 
significant response, whereas 400 µg/ml did not raised the response compared to 200 µg/ml. 
Selected concentrations are also supported by previous publications and they were well below 
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clinical concentrations (30mg/ml; 0,3-0,9ml) (Gestrelius et al 1997, Hoang et al 2000, Haase & 
Bartold 2001).  
 
The recombinant porcine amelogenin (rP172) was expressed in E. coli and isolated and 
characterised with mass spectrometry as previously described (Ryu et al 1999). EMD is 
predominantly amelogenin (>90%; Zeichner-David 2006), thus the amelogenin concentrations used 
were equal to the selected EMD concentrations. Recombinant human TGF-β1 was acquired from a 
supplier (Sigma-Aldrich, St. Louis, MO). Since the TGF-β1 concentration of EMD is unknown, the 
used TGF-β1 concentration of 10 ng/ml was selected based on previous publications (Pääkkönen et 
al 2008). 
 
All the study reagents were lyophilised and for the assays dissolved in PBS. To maximise the 
dissociation of study reagents to PBS the solutions were gently mixed 24 h in RT.  
 
5.3 EMD degradation assays (I) 
 
Several different EMD concentrations as well as both lyophilised EMD and EMD-gel were first 
tested to produce high quality gels. 9 mg/ml EMD-gel embedded in the 11% SDS-PAGE, instead of 
the normally-used gelatin (Laemmli 1970), was selected to be used in these studies. To detect 
EMD-degrading enzymes in GCF, the GCF samples were dissolved in TNC-buffer (50 mM Tris, 
0.2 M NaCl, 1 mM CaCl2, pH 7.8) and the same volume (15 µl/well) of each of the 156 GCF 
samples was loaded onto an EMD-embedded zymography gel. 
 
The study also aimed to compare the degradation profile caused by GCF to the degradation profile 
caused by MMPs. Therefore, recombinant human MMPs -1, -2, -8, -9, -13 and -14 (Chemicon, 
Temecula, CA; Invitek, Berlin, Germany; Calbiochem, San Diego, CA) were loaded (200 ng in 3 
µl/well) onto a separate EMD-embedded gel. After electrophoresis, the gels were washed twice 
with 2.5% Trixon X-100 buffer to renature the gelatinases. The gels were then incubated in TNC-
buffer 72 h at 37°C, and subsequently stained with 0.5% Coomassie Brilliant Blue R-250. The 
intensities of separate bands were scanned and measured quantitatively using optical densitometry 
and Quantity One software (Bio Rad Model GS-700 Imaging Densitometer, Bio-Rad, Richmond, 
CA, USA). To eliminate the background disturbance of the relatively diffuse bands, the analyses 
were done strictly at 97, 50 and 37 kDa and using equal sized boxes in every parallel gel.  
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5.4 Cell lines and cell cultures (I, II, III) 
 
In vitro experiments were carried out using one malignant and two different benign cell lines. 
Malignant cells were highly invasive HSC-3 tongue squamous cell carcinoma cells (Japan Health 
Science Resources Bank, JRCB 0623). Benign cells were human oral mucosal keratinocytes 
(HMKs) and human periodontal ligament fibroblasts (PLFs), which were obtained from surgical 
gingival biopsy or by scraping intact premolars as described previously (Mäkelä et al 1999, 
Oikarinen & Seppä 1987).   
 
The cells were cultured at 37°C in a humidified atmosphere and in their normal media containing 
per 100 ml for HSC-3 cells: 45 ml Dulbecco’s modified Eagle’s medium (DMEM), 45 ml Ham’s 
Nutrient Mixture F-12, 10 ml fetal calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, 50 
units/ml nystatin, 250 ng/ml Fungizone®, 1 mM sodium pyruvate, 2 nM L-glutamine and 0.4 ng/ml 
hydrocortisone; for HMKs: Keratinocyte-SFM supplement and Supplements For Keratinocyte-
SFM, including human recombinant epidermal growth factor (EGF 1-53) and bovine pituitary 
extract, 1 % penicillin and 0.1 % Fungizone®; and for PLFs: 90 ml DMEM, 10 ml fetal calf serum, 
100 units/ml penicillin, 100 µg/ml streptomycin and 250 ng/ml Fungizone®; and for PLFs: 90 ml 
Dulbecco’s modified Eagle’s medium, 10 ml fetal calf serum, 100 units/ml penicillin, 100 µg/ml 
streptomycin, and 250 ng/ml Fungizone® (All supplements excluding hydrocortisone: Life 
Technologies, Paisley, Scotland. Hydrocortisone: Diosynth, Oss, Netherlands). 
 
5.5 In vitro cell proliferation, migration, wound closure and adhesion assays (I, II)  
 
Periodontal ligament fibroblast proliferation assay (I) 
 
To determinate in vitro the consequences of the degradation of EMD caused by GCF, the effects of 
EMD with or without GCF and also the effects of recombinant amelogenin on the proliferation of 
PLFs were studied. The cells were culture in serum containing media on 96-well culture plate at the 
density of 5000/well (N=6). Before adding the study reagents, the cells were allowed to attach and 
grow overnight. The GCF samples dissolved in TNC-buffer were pooled from all diseased and 
healthy samples and sterile filtered before adding 10 µl/well with or without EMD (100 and 200 
µg/ml). Recombinant amelogenin (100 and 200 µg/ml) was used without GCF. The control cells 
were incubated with or without TNC-buffer (10 µl/well). After 48 h incubation, the proliferation of 
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PLFs was determined with the commercial Cell Proliferation ELISA BrdU kit (Roche Diagnostics, 
Mannheim, Germany) according to the manufacturer’s instructions. 
 
Human oral carcinoma cells and benign keratinocytes proliferation assay (II) 
 
The effect of EMD on the proliferation of HSC-3 and HMK cells was studied by culturing the cells 
in 96-well plates and in their normal medium for 24 h before adding EMD to give concentrations of 
0, 100 or 200 µg/ml.  The cells were incubated again for 12, 24, 48, 72 and 96 h followed by the 
ELISA proliferation analysis.  
 
Apoptosis (II) 
 
Apoptosis of HSC-3 and HMK cells was determined using Annexin-V-Fluos® (Roche Diagnostics, 
Penzberg, Germany) and propidium iodide (Roche Diagnostics, Indianapolis, IN) according to 
manufacturer’s instructions.  
 
Transmigration assay (II) 
 
Cell migration was studied using 8.0 µm-pore size and 6.5 µm-diameter Transwell® inserts (Costar, 
Cambridge, MA). Before plating, the cells were pre-incubated with 100 or 200 µg/ml EMD for 2 h 
at RT. The cells were allowed to migrate overnight and fixed with 10% trichloroacetic acid (TCA). 
The cells that had not migrated through the filter were removed and cells on the lower side were 
stained with crystal violet and either counted microscopically (HSC-3) or by scanning (HMK) (Bio 
Rad Model GS-700 Imaging Densitometer, Bio-Rad, Richmond, CA, US).  
 
To examine whether the increased migration of HSC-3 is due to active MMP-2 or -9, a cyclic 
peptide CTT-2 (50 µg/ml) that specifically inhibits gelatinolytic activities of MMP-2 and -9 but not 
of other MMPs was added to the transmigration assay with or without EMD (100 or 200 µg/ml) 
(Koivunen et al 1999, Heikkilä et al 2006).  
 
In vitro wound closure (II) 
 
Two-well chamber plates were pre-coated with BSA, and then 1x106 HSC-3 and HMKs were 
incubated for 1 h in the wells. After pre-incubation the culture plates were wounded with a sterile 
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pipette tip, washed with PBS and exposed to medium containing 0, 10 or 100 µg/ml EMD and 
cultured overnight. After incubation, the cultures were fixed with 10 % TCA and stained. The 
wounds were scanned and printed, and the wounded area was determined by comparing the weight 
of wounds to the control (Bio Rad Model GS-700 Imaging Densitometer, Bio-Rad, Richmond, CA, 
USA). 
 
In vitro cell adhesion assay (II) 
 
For the cell adhesion assay, 96-well plates were coated with EMD (10 µg/ml), fibronectin (10 
µg/ml, Sigma), BM components containing Matrigel (1:10 in PBS, Becton Dickinson, Bedford, 
MA) or BSA (10 µg/ml, Sigma) and left overnight at RT. HSC-3 and HMK cells were then plated 
at 10 000 cells/well and incubated for 2 h. The non-adherent cells were rinsed off and the remaining 
cells were fixed with 10 % TCA, stained and quantified using an ELISA reader at 540 nm. The 
adhesion study was repeated using the same coating components as described above, but prior to 
the experiments the cells were pre-incubated 2 h with EMD (100 µg/ml).  
 
5.6 In vitro MMP production assays (II, III, unpublished data) 
 
Gelatin zymography (II) 
 
In order to determine the effects of EMD on gelatinolytic enzymes produced by HSC-3 carcinoma 
cells and periodontal fibroblasts, a gelatin zymography of the culture medium was conducted. HSC-
3 cells at a density of 28 000/well and PLFs at 30 000/well were allowed to grow to sub-confluence 
in 24-well plates. The HSC-3 medium was replaced with serum-free medium and 0, 100 or 200 
µg/ml EMD was added to both assays. Cells were incubated for 48 h and medium collected, briefly 
centrifuged and stored at –20°C. The medium was added to 10 % SDS-PAGE containing 1 mg/ml 
of fluorescently labeled gelatin (Sutinen et al 1998). After electrophoresis, the gels were washed, 
incubated overnight and stained as described above. The intensities of separate bands were 
measured quantitatively using optical densitometry and Quantity one software (Bio Rad Model GS-
700 Imaging Densitometer, Bio-Rad, Richmond, CA, USA). 
 
ELISA immunosorbent assay (II) 
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To confirm the effects of EMD on gelatinolytic MMPs observed by zymography, an 
immunosorbent assay was done on HSC-3 culture medium. After 48 h of EMD incubation (0, 100 
and 200 µg/ml) the MMP-2 and MMP-9 concentrations were analyzed by a commercial ELISA 
assay according to the manufacturer's instructions (Biotrak, Amersham Pharmacia Biotech, 
Buckinghamshire, UK). 
 
Western immunoblotting (III) 
 
HSC-3 cells at 28 000/well were cultured in serum-free media with EMD (0, 100 or 200 µg/ml) for 
24 h. Western blotting for MMP-10 from culture media was carried out as previously described 
(Nyberg et al 2003). After SDS-PAGE gel electrophoresis the membrane was incubated with 
human monoclonal MMP-10 antibody (1:1000, R&D systems, Minneapolis, MN).  
 
5.7 Affymetrix cDNA microarrays (III) 
 
Microarray sample preparation and hybridization 
 
To assure an adequate amount of RNA, 1x106 HSC-3 cells/flask were seeded and allowed to grow 
in their normal media overnight. The study reagents TGF-β1 (10 ng/ml) and EMD (200 µg/ml) 
were dissolved from the PBS-stock solutions to serum containing culture media, and the media was 
changed. Equal volume of PBS was also added to control cells when the culture media of the cells 
was changed. After 6 h and 24 h of incubation the total cellular RNA was extracted using the 
Qiagen RNeasy Mini Kit according to the manufacturer’s instructions (Quiagen, Oslo, Norway). 
RNA quality and quantity were determined using the Agilent 2100 Bioanalyzer (Agilent 
Technologies, DE, USA). Micro-array experiments were carried out using the Affymetrix Human 
Genome U133 Plus 2.0 chip, for analysis of over 47,000 transcripts. Total RNA (8 µg) from each 
sample was used for target cDNA synthesis according to the Affymetrix protocol 
(www.affymetrix.com). Three biological replicates were produced at each time point (Lee & 
Whitmore 2002) 
 
Gene Ontology enrichment analysis 
 
For the differentially expressed genes, Gene Ontology (GO) enrichment analysis was performed 
using the DAVID annotation tool (http://david.abcc.ncifcrf.gov/home.jsp) according to Huang et al 
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(2009). The analysis was conducted using the list of all statistically significantly up- and down-
regulated genes separately. The whole genome list of the Human Genome U133 Plus 2.0 chip was 
used as a background. An EASE score (E-score), which is a modified Fisher Exact P-Value, was 
used to identify enriched categories. An E-score of <0.05 was considered statistically significant. 
Furthermore, the enriched terms were grouped into functional clusters according to terms having 
similar biological meaning due to sharing similar gene members. 
 
5.8 Mouse experiments (II) 
 
The animal experiment was approved by the Ethics Committee for Animal Experimentation in the 
State Provincial Office of Southern Finland.  For inoculation, the 1x107 detached HSC-3 cells 
diluted and suspended in 200 µl serum-free culture medium were injected subcutaneously into the 
right and left back of twenty 6- to 8-week old Harlan-Spraque Dawley athymic nude mice. On days 
4-8 after the inoculation, ten mice were daily injected subcutaneously with 100 µg/ml EMD in 200 
µl saline, whereas ten control mice were daily injected with the same volume (200 µl) of saline. 
Three times a week the mice were weighted, the tumour growth measured and the survival 
observed. The criteria for euthanasia were tumour size over 10 mm in diameter, weight loss of more 
than 15 %, or symptoms of suffering. After euthanasia, the mice were dissected and enlarged 
axillary and peritoneal lymph nodes (n=6) were collected for metastasis analysis. The presence of 
metastasis in the lymph nodes was confirmed histologically.       
 
5.9 Data collection for the systematic review (IV) 
 
An information specialist-assisted search was made from PubMed and EMBASE databases. The 
search terms were Emdogain and/or ‘enamel matrix derivative’ and language definition English. 
The publication date was restricted to the period of January 1997 to December 2008. Altogether 
403 publications were found. No clinical reports concerning association of Emdogain with oral 
carcinoma were found. Thus, the review was restricted to in vitro studies and the criteria for a 
systematic review was applied after the in vivo exclusion.  
Thus, exclusion criteria were: 
1) Article not written in English 
2) Clinical studies, e.g. studies dealing with radiology or treatment techniques, outcomes and 
surveys. 
3) In vivo and in vitro studies concerning histology, immunohistocemistry, etc. 
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4) In vitro studies designed to study bacteria or cells other than oral cells or malignant cells. 
5) Review articles and conference reports. 
Altogether 76 in vitro studies were included in this study, designed to obtain all available biological 
data relevant for carcinoma-related factors and the behaviour of oral cells. Thus, inclusion criteria 
were: 
1) Articles published in English between 1. January 1997 and 31. December 2008. 
2) Assays designed to study human cells present in oral tissues or malignant cells. 
3) Assays designed to study cytokines in Emdogain or regulated by Emdogain. 
 
5.10 Statistical analysis (I,II,III)  
 
Analysis of variance models was used to estimate the effects of the experimental substrates on the 
various in vitro outcomes. The results are presented as relative comparisons of means between 
relevant treatment groups, expressed in terms of fold change or percentage from a given baseline, 
together with the 95% confidence intervals (CI). In study I, the CI was calculated with the web-
based Texas University Confidence Interval Calculator 
(http://www.stat.tamu.edu/~jhardin/applets/index.html). In study II, the R environment for 
statistical computing and graphics was used in computations, especially the function lm() for fitting 
linear models (URL:www.R-project.org.).  
 
Reporting statistical significance using P-values has deliberately been avoided where possible. 
Instead, statistical certainty/uncertainty has been expressed using 95% confidence intervals, which 
are known to be more informative than P-values. When reporting the 95% confidence intervals 
(CI), it means that the data is well consistent within these limits. At the same time, the CIs point out 
the effect size and error margins. In addition, the ’statistical significance’ can also be judged when 
CIs are present. In contrast, P-value is generally uninformative, fails to convey important 
information about effect size and is often misleading (lack or over emphasis of the biological 
relevance). This statistical method follows also the explicit recommendations given by leading 
medical journals (Brennan et al 1994, Sterne et al 2001), and these recommendations are also 
adopted in the Uniform Requirements for Manuscripts from 1988 onwards (International 
Committee of Medical Journal Editors. Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, URL:www.icmje.org). However, the P-values are presented for the 
microarray data and a P-value of <0.05 is considered statistically significant. 
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Microarray data analysis 
 
The microarray data analysis was performed using open source Chipster software 
(http://chipster.csc.fi). For normalization, the Robust Multi-Array method was used. The regulated 
genes by EMD and TGF-β1 were compared with the gene list of the control cells by using the 
empirical Bayes t-test to estimate the statistical significance of individual genes with a cut-off 
threshold of P<0.05. The fold change (FC) of the statistically significantly regulated genes was also 
calculated.  
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6 RESULTS 
 
6.1 Degradation of EMD by GCF and MMP (I) 
 
GCF was observed to be capable of degrading EMD-embedded zymography gels. The degradation 
depended on the state of periodontal disease, with statistically significantly more degradation 
observed in all states of periodontal disease (gingivitis, chronic periodontitis and aggressive 
periodontitis) compared to healthy control GCF.  
 
To further determine the EMD-degrading proteases observed in periodontic GCF, the effects of 
recombinant human MMPs -1, -2, -8, -9, -13 and -14 on EMD- embedded gels were studied. Only 
MMPs -2 and -8 caused barely detectable lysis of the gel and in a restricted range compared to GCF 
samples. 
 
6.2 In vitro cell proliferation, viability and behaviour assays (I, II) 
 
Effects of EMD, GCF and amelogenin on the proliferation of periodontal ligament fibroblasts  
 
The proliferation of PLFs was markedly induced by EMD (100 µg/ml and 200 µg/ml) after 24 and 
48 h of incubations compared with the untreated controls. When the cells were treated with EMD 
together with GCF (10 µg/ml; dissolved in TNC-buffer), the induction of the proliferation of PLFs 
by EMD was decreased compared to treatment with EMD alone. Thus, EMD at the lower 
concentration of 100 µg/ml together with GCF could not induce the proliferation of PLFs. The GCF 
alone as well as TNC-buffer alone had no effect on the proliferation of PLFs (data regarding TNC-
buffer not shown). Amelogenin, the most abundant protein in EMD, had a drastic inhibitory effect 
on the proliferation of PLFs. On average, 200 µg/ml amelogenin caused a 54% decrease in the 
proliferation of PLFs with respect to control. 
 
Effects of EMD on the proliferation and apoptosis of carcinoma cells 
 
In HSC-3 cell proliferation, no differences were found between the control and the EMD-treated 
(100 and 200 µg/ml) cells after 12, 24, 48, 72, and 96 h of incubation. Furthermore, EMD (100 and 
200 µg/ml) had no effect on apoptosis of HSC-3 or HMK cells. 
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Effects of EMD on in vitro migration and wound closure of carcinoma cells 
 
EMD stimulated the random migration of HSC-3 cells in Transwell-assays during overnight culture. 
EMD at 100 µg/ml increased the migration of HSC-3 cells by 43% (95% CI: 21% to 69%) and at 
200 µg/ml by 57% (95% CI: 33% to 86%) in relation to control. EMD had no effect on the 
migration of benign HMK cells. 
 
CTT-2 (50 µg/ml), a selective inhibitor of MMP-2 and -9, decreased the migration of HSC-3 
carcinoma cells by 89% (95% CI: 65% to 97%) compared to the control. In combination with EMD 
at 100 µg/ml, CTT-2 decreased the migration by 97 % (95% CI: 91% to 99%), but with EMD at 
200 µg/ml the observed migration was decreased to only 57% of the control level (95 % CI: -87% 
to +41%). CTT-2 (50 µg/ml) also decreased the migration of benign HMK cells.  
 
EMD was able to induce in vitro wound closure of carcinoma cells, which requires both cell 
proliferation and migration. In the beginning of the assay the mean of the wounded areas of HSC-3 
cells was 46 mm2 (SD 7.1 mm2). After 24 h incubation the mean areas of control wounds were 
reduced to 35.2 mm2 (SD 13.8 mm2). EMD at 10 µg/ml concentration decreased the wound areas 
by 51% (95% CI: 10% to 74%), and at 100 µg/ml by about a similar amount: 57% (95% CI: 20% to 
77%) compared to the control wounds.  
 
Effects of EMD on carcinoma cell adhesion 
 
EMD was able to alter the attachment of HSC-3 cells to various extracellular matrix components. 
The mean attachment of HSC-3 cells was similar for both EMD and BSA coated surfaces. Matrigel 
and fibronectin coating increased the attachment of HSC-3 cells relative to BSA by 20% (95% CI: 
14% to 26%) and by 8% (95% CI: 4% to 13%), respectively. Pre-incubation with EMD-containing 
medium (100 µg/ml) followed by the adhesion experiment increased the HSC-3 adhesion to BSA 
by 10% (95% CI: 5% to 16%), to fibronectin by 11% (95% CI: 5% to 16%), but decreased the 
adhesion to Matrigel by 7% (95% CI: 2% to 11%), whereas the effect on the adhesion to EMD was 
unclear, the observed increase being 3% (95% CI: -2% to +9%) 
 
6.3 Effects of EMD on the in-vitro production of matrix metalloproteinases  (II, III, un-
published data) 
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Emdogain-induced production of MMP-2 by periodontal ligament fibroblasts 
 
The production of 72 kDa pro-MMP-2 was observed to be induced by EMD in the conditioned 
medium of periodontal ligament fibroblasts when analysed with gelatin zymography. The induced 
pro-MMP-2 production was on average 1.7-fold (95% CI: 1.5 to 1.8) with EMD at 100 µg/ml and 
1.8-fold (CI 1.6 to 2.0) with EMD at 200 µg/ml with respect to control. 
 
 
Figure 5. An example of a gelatin zymography gel from the culture medium of periodontal 
ligament fibroblasts. EMD dose-dependently induced pro-MMP-2 production.  
 
Emdogain-induced production of MMP-2, MMP-9 and MMP-10 by carcinoma cells 
 
The production of 72 kDa pro-MMP-2 and 92 kDa pro-MMP-9 was markedly induced by EMD in 
the conditioned medium of HSC-3 carcinoma cells when analyzed with gelatin zymography. The 
induction caused by EMD was also stronger in carcinoma cells than in periodontal ligament 
fibroblasts. The induced pro-MMP-2 production was on average 2.3-fold (95% CI: 1.6 to 3.2) with 
EMD at 100 µg/ml and 2.6-fold (95% CI: 1.8 to 3.7) with EMD at 200 µg/ml with respect to 
control. The induced pro-MMP-9 ratios were 2.4-fold (95% CI: 2.0 to 2.8) with EMD at 100 µg/ml 
and 2.3-fold (95% CI: 1.9 to 2.7) with EMD at 200 µg/ml with respect to control. The production of 
MMP-2 and MMP-9 was similarly induced by EMD in the conditioned medium of HSC-3 cells 
analyzed with ELISA.  
 
Western immunoblots showed that the untreated HSC-3 cells did not produce MMP-10 but the 
production was clearly induced at both EMD concentrations (100 and 200 µg/ml) after 24 h of 
incubation.   
 
6.4 Effects of EMD and TGF-β1 on the gene profile of carcinoma cells (III) 
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Comparison of the genes regulated by TGF-β1 and EMD treatment 
 
The Affymetrix microarray revealed a total of 32 genes to be statistically significantly (P<0.05) up-
regulated and 16 genes down-regulated in HSC-3 carcinoma cells after 6 h of EMD treatment 
compared to untreated control cells. After 24 h of EMD incubation, this effect on the regulated 
genes (P<0.05) was attenuated, showing only four up-regulated and eight down-regulated genes. 
TGF-β1 altered regulation of markedly more genes than EMD after 6 h and 24 h of treatment. A 
total of 239 genes were statistically significantly (P<0.05) up-regulated and 154 genes down-
regulated in HSC-3 cells after 6 h of TGF-β1 treatment compared to untreated control cells. After 
24 h of TGF-β1 incubation, a total of 242 genes were up-regulated and 104 genes down-regulated 
compared to untreated carcinoma cells.  
 
About half (53%) of the genes (n=17) up-regulated by the 6 h EMD treatment were the same as 
those up-regulated by the 6 h TGF-β1 treatment. Five (31%) of the genes down-regulated by EMD 
were the same as those by TGF-β1. Of the four up- and eight down-regulated genes at 24 h of EMD 
treatment, two up- and two down-regulated genes were the same as those affected by the TGF-β1 
treatment. 
 
Effects of EMD and TGF-β1 on MMP family genes 
 
MMP-9 was the most significantly (P<0.05) up-regulated of all the genes after 24 h of EMD 
treatment as well as after 6 and 24 h of TGF-β1 treatments. MMP-10 was the most up-regulated 
gene after 6 h of EMD treatment, but was then the most down-regulated gene after 24 h. In TGF-β1 
treated carcinoma cells, MMP-10 was first among the most up-regulated genes after 6 h of 
treatment but was then absent at 24 h. Furthermore, MMP-1 was also statistically significantly up-
regulated after 6 and 24 h of TGF-β1 treatments. 
 
Effects of EMD and TGF-β1 on Gene Ontology (GO) groups 
 
GO enrichment analysis revealed several enriched terms after 6 h EMD treatment (Appendix 1). 
After grouping the enriched terms into functional clusters, the analysis revealed keratinocyte 
differentiation, inflammatory response and proteolysis to be the most up-regulated. Among the 
down-regulated genes, the most enriched clusters were cell growth and morphogenesis, circulatory 
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system and cellular developmental processes. Because of the relatively few genes regulated by 
EMD after 24 h, the GO enrichment analysis was not performed for that treatment.  
 
GO analysis of 6 h TGF-β1 treatment revealed several enriched terms (Appendix 1), which were 
grouped into functional clusters. The most enriched clusters among up-regulated genes were system 
development, chemokine activity/inflammatory response, hemopoiesis and angiogenesis. Those 
among down-regulated clusters were cell cycle processes, mitosis/M-phase and cell growth. After 
24 h TGF-β1 treatment, the most enriched clusters among up-regulated genes were developmental 
processes, inflammatory/defence response and angiogenesis. Down-regulated clusters were 
regulation of cellular processes, intracellular organelle and calcium homeostasis. 
 
6.5 Effects of EMD on metastasis formation in vivo (II) 
 
The mean number of enlarged lymph nodes containing metastases was 3.1 (range 1 to 5, SD 1.6) in 
the EMD group, and 1.5 (SD 0.9) in the NaCl group, the difference being 1.6 (CI 0.2 to 2.8). The 
evidence was insufficient to determine whether there were differences in mortality between the two 
groups. 
 
6.6 Results of the systematic review (IV) 
 
Altogether 76 studies were found to meet the inclusion criteria, e.g. in vitro studies concerning 
cytokines in EMD or regulated by EMD and assays designed to study the effects of EMD on human 
oral cells or malignant cells. EMD was found to enhance the in vitro production of several factors 
related to carcinogenesis in malignant and benign cell lines. TGF-β1 and MMPs are crucial 
regulators in carcinogenesis and their production is enhanced by EMD in many different cell lines 
including osteoblasts, fibroblasts and malignant osteosarcoma cells (Schwartz et al 2000, 
Mirastschijski 2004, Goda et al 2008). In addition, EMD promotes the production of several other 
carcinogenesis-related cytokines by benign cells. These include CTGF, FGF-2, ALP and 
osteopontin produced by osteoblasts; IGF-I, PDGF, VEGF, IL-6, ALP and OPG produced by PDL 
fibroblasts; and PDGF, VEGF and osteopontin produced by epithelial-derived cells (Hakki et al 
2001, Rincon et al 2005). Together with the effects of EMD on production of MMP- and TGF-β1 
by malignant cells, EMD also stimulates collagenolysis by osteosarcoma cells (Goda et al 2008). 
Furthermore, EMD increases cAMP levels and PDGF-AB production of HeLa cells and stimulates 
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phosphorylation of several MAP family kinases in SCC-25 cells (Lyngstadaas et al 2001, Kawase et 
al 2001, 2002). Despite these findings, EMD has been shown to possess negligible or inhibitory 
effects on the proliferation of malignant cells and to inhibit breast cancer cell attachment to bone 
matrix (Gestrelius et al 1997, Schwartz 2000, Lyngstadaas 2001, Kawase et al 2001, Takayama 
2005).  
 
Table 1. In vitro effects of Emdogain on carcinogenesis-related cytokines and cellular processes in 
malignant and benign cell lines. [+] corresponds to stimulatory, [−] to inhibitory, [0] to unchanged 
and [X] to non-relevant effects of EMD on the corresponding carcinogenesis-related variable. Each 
symbol [+], [−] and [0] corresponds to one study, or to one cell line when several cell lines were 
studied. 
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7 DISCUSSION 
 
7.1 Summary of the main results 
 
The aim of the study was to examine whether gingival crevicular fluid (GCF), which contains 
several different proteolytic enzymes, could degrade EMD and alter its biological functions. In 
addition, the objective was to study the effects of EMD on carcinogenesis-related factors, in 
particular MMPs, using in vitro and in vivo models. This study also aimed to contribute to the 
understanding of the composition of EMD.  
 
GCF was observed to degrade EMD depending on the level and severity of the periodontal disease. 
The GCF-degraded EMD was less effective in enhancing PLF proliferation than non-degraded 
EMD. EMD was observed to enhance the proliferation of PLFs whereas amelogenin inhibited the 
proliferation. In contrast, TGF-β1 was more effective and regulated more genes in HSC-3 cells than 
EMD.  EMD was capable of enhancing in vitro migration and wound closure of HSC-3 cells and to 
promote metastasis formation in vivo. In addition, EMD was capable of inducing MMP-2, MMP-9 
and MMP-10 production at the protein level and MMP- 9 and MMP-10 expression at the gene 
level.  
 
7.2 EMD in periodontal regeneration 
 
The mechanisms of action and the exact composition of Emdogain are not completely clear. In 
addition, a systematic Cochrane review suggests that the overall treatment effect of EMD might be 
overestimated and that the actual clinical advantages of using EMD are unknown (Esposito et al 
2005). Despite the lack of knowledge, EMD is extensively used in regenerative periodontal therapy 
in all kinds of patients including medically compromised subjects. Periodontal inflammation is 
characterised by increased apical proliferation of gingival sulcular epithelial cells together with 
increased activity of proteolytic enzymes in gingival tissue and GCF. Matrix metalloproteinases 
(MMPs) and matrix-degrading serine proteinases have been shown to be the main mediators of 
pathologic tissue destruction in periodontitis (Sorsa et al 2004, 2006). These proteinases, in 
particular MMPs, can degrade most, if not all, extracellular matrix and basement membrane 
components of periodontium (Birkedal-Hansen et al 1993, Sorsa et al 2004, 2006).  
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In periodontal treatment, a full-thickness flap procedure is used to apply the EMD in the deepest 
periodontal pockets and in contact with periodontally-exposed root surfaces. Detectable amounts of 
EMD remain at the site of application on the root surface for two to four weeks after which EMD is 
degraded (Gestrelius et al 1997, www.straumann.com). This degradation is presumably due to 
proteolytic enzymes present post-operatively and during the healing process in connective tissue 
and thus secreted also in GCF.  
 
The tissue breakdown and healing after the periodontal therapy and after the surgical trauma 
involve collagen destruction via an MMP-mediated pathway (Birkedal-Hansen 1993, Kinane et al 
2003). It has been shown that non-surgical periodontal therapy decreases the MMP levels of GCF 
weeks to months after periodontal therapy (Haerian et al 1996, Kinane et al 2003, Marcaccini et al 
2010). However, the MMP levels of GCF are not statistically significantly reduced during the 
healing period of the first weeks (Kinane et al 2003,) or in sites that do not respond to the treatment 
(Mäntylä et al 2003). Furthermore, it has been shown that periodontitis-affected sites continue to 
display high levels of MMP-8 and collagenolytic activity also after effective periodontal treatment, 
and these levels and activity are in the range of those found in gingivitis (Figueredo et al 2004).  
 
In this study it was observed that GCF can, depending on the periodontal status, degrade EMD. 
Clinically EMD is not directly interacting with GCF but with the connective tissue fluids instead. 
Furthermore, EMD should only be used after infection control and proper scaling and root planing. 
In this assay, GCF was mainly used to mimic the circumstances and proteases present in connective 
tissue after periodontal therapy. Thus, the strongest EMD degrading effect caused by GCF from 
chronic periodontitis states may be clinically overestimated. However, also healthy GCF was 
capable of degrading EMD, thus implicating that connective tissue fluids are capable of degrading 
EMD also after the periodontal therapy.  
 
In addition, this study suggest, that MMPs are not the main factors contributing to the observed 
degradation, since only MMPs-2 and -8 were capable of degrading EMD, and only to a relatively 
low extent. The results suggest that the role of other proteases in GCF are most likely more 
important for the degradation of the EMD in vivo. Interestingly, both metalloendoproteinase and 
serine protease activities have also been observed in EMD itself (Maycock et al 2002).  
 
The effects of EMD on the proliferation of periodontal ligament fibroblasts have been extensively 
studied. Also, the observations of the present study confirmed that EMD can enhance the 
 46
proliferation of PLFs in vitro. Surprisingly, the recombinant amelogenin protein was observed to 
depress the proliferation of PLFs significantly. This observation suggests, as Chong et al (2006) 
have previously postulated, that amelogenin itself has very little to do with the proliferation of 
periodontal ligament fibroblasts, and that the stimulatory effect of EMD on the proliferation of 
PLFs is caused by other factors in EMD. Another novel observation was that EMD together with 
GCF was less effective in promoting the proliferation than EMD alone, and with the lower 
concentration of EMD (100 µg/ml) the proliferation was not different from that of the control cells. 
These results suggest that GCF can degrade or inactivate the growth factor-like molecules in EMD 
responsible for proliferation. It should also be noted that due to the high consumption of GCF in 
these assays, the GCF samples were pooled, and thus the assay also contained less effective EMD-
degrading GCF from healthy subjects. Thus, this approach is also closer to clinical circumstances 
where EMD is not in contact with chronically infected tissues, but healing tissues instead. Taking 
these observations together, it can be concluded that the inductive effects of EMD on the 
proliferation of PLFs are not caused by amelogenin, and thus the presence of cytokines in EMD is 
presumable. In addition, the stimulatory effect of EMD on the proliferation of PLFs, one of the 
most crucial steps in periodontal regeneration, may be inhibited if the product comes in contact with 
proteolytic enzymes in periodontal tissues also in vivo. 
 
7.3 EMD and carcinogenesis 
 
As stated above, the overall knowledge of the effects of EMD on periodontal tissues is relatively 
good. However, many relevant issues, including the cytokine content of EMD, still remain 
unresolved. There is evidence suggesting that the epithelial-mesenchymal interactions are important 
during periodontal tissue development and regeneration, and that EMD can mimic these processes 
(Gestrelius et al 2000). In carcinogenesis, epithelial-mesenchymal interactions act in an 
uncontrolled manner and one of the first steps towards malignancy is the epithelial to mesenchymal 
transition. After the initial formation of the epithelial malignancy, tumour growth depends on the 
proteolytic enzymes and cytokines produced by stromal cells surrounding the tumour. EMD has 
been observed to stimulate the production of several cytokines and cellular processes normally 
related to periodontal regeneration but also to carcinogenesis (See Table 1).  
 
One of the major cytokines in carcinogenesis is TGF-β1. TGF-β1 stimulates cell growth, MMP 
production, angiogenesis, invasion and metastasis in head and neck squamous cell carcinomas 
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(HNSCC) (Derynck et al 2001, Akhurst et al 2001). In addition, TGF-β1 together with other 
cytokines, for example those in epidermal growth factor families, can enhance morphological and 
invasive phases of the EMT phenotype (Wilkins-Port and Higgins 2007). The present study 
examined the effects of TGF-β1 on gene expression of carcinoma cells using Affymetrix 
microarrays. TGF-β1 was observed to induce angiogenesis-related genes but to down-regulate 
proliferation-related genes in carcinoma cells after 6 h of incubation. However, the inhibitory effect 
of TGF-β1 on the proliferation of carcinoma cells was only temporary and was absent after 24 h, 
whereas the stimulatory effect of TGF-β1 on angiogenesis remained constant over the observation 
period.  
 
EMD has been postulated to contain TGF-β1 (Kawase et al 2001, Suzuki et al 2005) and to enhance 
the production of TGF-β1 by several cell lines (Schwartz et al 2000). In the present study, when the 
effects of EMD and TGF-β1 on carcinoma cell gene expression were compared, TGF-β1 was 
observed to regulate markedly more genes than EMD. This result suggests that EMD might not 
contain TGF-β1, or that the cytokine is present in other concentrations as studied here. The latter 
assumption is supported by the result showing, that the expression of TGF-β family genes was 
down-regulated by EMD. Thus, EMD may contain TGF-β1 or have TGF-β1-like activity. In 
addition, several regulatory functions for both of the study reagents were similar, for example both 
EMD and TGF-β1 up-regulated the expression of MMP-9 and MMP-10 in carcinoma cells. Thus, 
this study cannot confirm or reject the hypothesis that EMD contains TGF-β1.   
 
Together with TGF-β1, MMPs are considered to be crucial in tumorigenesis (Lόpez-Otίn & 
Matrisian 2007). Typically, several MMPs are expressed in human malignant tumours, and elevated 
MMP levels correlate with aggressive and invasive tumours and poor prognosis (Stetler-Stevenson 
& Yu 2001). MMPs have an important role at all stages of tumorigenesis: they enhance tumour-
induced angiogenesis, regulate and activate growth factors, and break down ECM and BM to allow 
tumour cell invasion and metastatic spread (McCawley & Matrisian 2000; Liotta and Kohn 2001; 
Stetler-Stevenson & Yu 2001, Nyberg et al 2008). In this study EMD was observed to enhance the 
production of MMP-2 and MMP-9 by carcinoma cells as well as by non-malignant keratinocytes. 
The MMPs from the culture media of different assays were analysed both by gelatin zymography 
and ELISA immunosorbent assay. The present study confirmed EMD-induced up-regulation of 
MMPs at the gene level and the production of MMP-10 in protein level. In addition, the GO 
enrichment analysis revealed the term proteolysis being one of the most up-regulated by carcinoma 
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cells after EMD incubation. Also, EMD-induced migration of carcinoma cells was observed to 
depend on MMP-2 and -9, since an inhibitor of these MMPs (CTT-2) arrested the effects of EMD 
on the migration. Thus, these studies provide extensive results showing EMD to be capable of 
regulating MMPs produced by oral carcinoma cells. In addition, other studies have confirmed that 
EMD can enhance the production of MMPs in different cell lines. Goda et al (2008) observed EMD 
to enhance the production of MMP-1 in malignant MG-63 osteosarcoma cells and to promote the in 
vitro degradation of type I collagen. In benign cells, it has been shown that EMD increases more 
that threefold the release of MMP-2 from cultured rat skin fibroblasts as well as from endothelial 
cells (Mirastschijski et al 2004). This effect of EMD on MMPs is highly interesting and may 
potentially cause carcinogenic effects. However, the effects of EMD on MMP production can also 
vary between cell lines, MMPs studied and according to other factors and cytokines present in vivo. 
As with carcinoma cells, EMD was also observed to enhance the MMP-2 production by periodontal 
ligament fibroblasts in vitro. However, EMD decreases the levels of MMP-1 and MMP-8 in GCF 
after flap surgery in vivo. In that study, the decreased MMP levels in GCF may just be due to the 
decreased inflammation in periodontal tissues after periodontal treatment.  Even then the result 
highlights the limits of in vitro studies and the variability in the response to different cytokines by 
different cell lines and tissues.     
 
As with the production of MMPs, the effects of EMD on other cellular functions also vary between 
the cell lines investigated. In this study, notably increased in vitro migration and wound closure of 
carcinoma cells were observed after EMD treatment. The effect of EMD on the migration and 
wound closure of benign keratinocytes (HMK cells) was less obvious. These findings with a shorter 
culture period are similar to previous findings in which enhanced wound-fill of osteosarcoma (MG-
63) cells was observed after a longer culture period (6 to 9 days) (Hoang et al 2000). According to 
the effects of EMD on migration and wound closure of carcinoma cells, it would be logical to find 
EMD to enhance the proliferation of carcinoma cells as well. However, it has been demonstrated 
that EMD has no effect on highly malignant MCF-7 breast carcinoma cell proliferation during short 
180 min incubations (Takayama et al 2005). The findings of the present study also demonstrated 
that EMD exhibits no effect on the proliferation of oral carcinoma cells after 12h to four days of 
treatment. In contrast, EMD inhibited HMK cell proliferation after 12 and 24 hours incubation. 
Kawase et al (2001) have shown that EMD inhibits the proliferation of human squamous cell 
carcinoma SCC-25 cells after three days of treatment. In the same study, it was also shown that 
EMD dose-dependently arrested the cell cycle of SCC-25 cells at G1 and did not discernibly 
increase SCC-25 apoptosis over 8 days of treatment. These results indicate that the effects of EMD 
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on cell proliferation are likely to depend on the cell type investigated. The discrepancy between the 
results with SCC-25 cells of Kawase et al (2001) and those with HSC-3 cells used in this study may 
reflect the fact that HSC-3 cells are highly invasive whereas the SCC-25 cells are moderately 
differentiated, less invasive and often, like in the study by Kawase et al (2001), used as a substitute 
for normal epithelial cells (Matsumoto et al 1989). Eventually, the less invasive carcinoma cells are 
likely to be more sensitive to the regulatory cell proliferation signals of EMD relative to more 
invasive and aggressive counterparts.  
 
After having observed carcinogenesis-related factors to be regulated in several in vitro assays, this 
study aimed to examine the effects of EMD on carcinogenesis in vivo. Despite the small number of 
study animals, ten subjects in the study group and ten in the control group, the inductive effect of 
EMD on metastasis was clear, and also statistically significant. Due to the small number of subjects 
no differences were observed in survival or tumour growth between the two study groups. Thus, a 
more extensive in vivo study would be needed to confirm the observed effects. 
 
In addition to the present study, only a few studies concerning EMD and malignant cells have been 
conducted. None of these have focused on carcinogenesis as such, but malignant cells have rather 
been used as an “easy growing” substitute for their benign precursors. Also, many of these assays 
have been carried out with cells very different from those in oral tissues. Thus, these studies are not 
of major relevance in the context of EMD and oral cancer. No matter their original scientific goals, 
the present study reviewed all in vitro studies in which malignant cells were treated with EMD. 
According to the reviewed studies, EMD has been shown to stimulate the production of several 
cytokines known to be up-regulated in carcinomas, including MMP-1, -2, -9, IL-6, TGF-β1 and 
PDGF. In addition, EMD can enhance the expression of these and several other cytokines by benign 
cells. In carcinogenesis, the cytokines produced by stromal cells surrounding the malignant tissue 
are crucial in regulating tumour behaviour and growth. Thus, in a situation in which EMD were 
present in direct contact with either malignant tissue or nearby normal tissue, EMD could be 
capable of promoting carcinogenesis by inducing cytokine production and transformation of the 
tissues. 
 
The initial hypothesis for the present study arose from a clinical observation in which a dysplastic 
lesion was converted into an invasive carcinoma shortly after EMD treatment. The presented 
clinical situation is rare, but it should be noted that according to the manufacturer of EMD 
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(Straumann, Basel, Switzerland), mucosal dysplasia is not a contraindication for EMD treatment. 
However, the treatment choices should not be based solely on the statements made by 
manufacturers, and performing a periodontal surgery to an area with an erosive and dysplastic 
lesions is not in accordance with the standard of care. In this case, the treatment should have 
included the management of the periodontal pocket by conventional scaling and root planing, 
together with the treatment of the mucous dysplastic lesions by local medication or by surgical 
means. In addition, when considering the possible causal role of Emdogain in the development of 
carcinoma, it should be noted that preceding factors existed, as the patient already had widespread 
dysplastic pre-malignant non-homogenous leukoplakia lesions. Before the EMD-therapy, several 
biopsies were taken around the mucous membranes, and also near the EMD-treated sites, showing 
moderate dysplasia. However, it is well known that the degree of dysplasia can vary from site to site 
and thus it may be possible that the patient already had a carcinoma in situ. Nonetheless, the 
location of the initial cancer within the bone, close to the apex of d.12, and the close chronological 
and spatial relationship to the EMD-treatment were unusual. Based on the follow-up history, it is 
highly possible that this patient had genetic susceptibility to dysplastic transition (“field 
cancerization”), since the recurrences of mucous dysplastic and cancer lesions have occurred 
several times during the recent past. However, the possibility of EMD influence on the cancer 
induction of this patient could not be completely ruled out. Further studies of the effects of EMD on 
cytokines produced by benign and malignant oral tissues together with studies focusing on the 
composition of EMD are needed before the actual safety of EMD on patient with dysplastic 
mucosal lesions can be confirmed. 
 
7.4 Methodological considerations 
 
The first sub-study examined whether the degradation of EMD caused by GCF has effects on the 
proliferation of PLFs. The proliferation was determined with a commercial Cell Proliferation 
ELISA BrdU kit. BrdU is incorporated into newly synthesised DNA, which is optically measured. 
Thus, the assay actually measures the DNA synthesis of the cells assumed to reflect the 
proliferation instead of directly measuring the proliferation of the cells. However, the method was 
selected because it is simple and sensitive, does not rely on microscopical counting of the cells, and 
is therefore objective and currently often used.   
 
The main result of the proliferation assay was that GCF together with EMD cannot stimulate the 
proliferation of PLFs, as EMD did alone. In addition, the GCF treatment alone had no effect on the 
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proliferation. During the proliferation assay, the cells were kept in serum containing media to 
simulate in vivo circumstances, in which the cells normally have enough nourishment. However, the 
high concentrations of serum in the media are likely to override the effects of tiny amounts of 
cytokines and other effectors in GCF. Thus, the result concerning the GCF only treated control cells 
may be interfered by the serum. However, this problem cannot cause bias to the main result of the 
study, as it was shown that GCF can degrade EMD or inactivate its effects despite the presence of 
serum.  
  
The general aim of the second and third sub-studies was to study whether EMD could induce 
carcinogenesis. This was studied with in vitro cell assays and in vivo mice experiment. With the 
selected in vitro assays, several crucial cellular processes related to carcinogenesis could be studied, 
including migration, proliferation and MMP production. However, carcinogenesis relies on several 
other factors as well which were not studied. These include the production of other MMPs and 
growth factors as well as the invasion capabilities of the cells. In addition, it has been shown that 
malignant cells with different phenotypes behave differently in various assays (Matsumoto et al 
1989). However, the assays in the present study were done using only one highly malignant cell 
line, the HSC-3 oral carcinoma cells. Furthermore, the selected in vitro assays were relatively 
simple and thus are not comparable with the in vivo circumstances in which the malignant cells are 
constantly interacting with the stromal cells and numerous different cytokines. Thus, the results 
from these in vitro studies are presumably partly cell type-specific, and cannot be directly 
generalised to all dysplastic cell types or to in vivo circumstances. 
 
In the present assays, EMD, amelogenin and TGF-β1 were dissolved in PBS. In previous studies, 
EMD has most often been dissolved in acidic acid (Hoang et al 2000), trifluoroacetic acid (Kawase 
et al 2000) or propylene glycol alginate (PGA, Yuan et al 2003) instead of PBS (Klein et al 2007). 
In the study, PBS was chosen because it is neutral and thus closer to the neutral pH of the oral 
cavity compared to the acids. However, enamel matrix proteins, in particular amelogenin, are 
hydrophobic and do not completely dissolve at neutral pH. To maximise the dissociation of EMD to 
PBS the solution was gently mixed 24 h in RT. Microscopically, EMD was observed to be properly 
dissolved in the culture media after incubation at +37°C. However, there is the possibility that some 
minority of the insoluble proteins may not have dissolved and were thus not present in the assays. 
This could cause slightly higher concentrations of the possible water-soluble growth factors in 
EMD in assays compared to studies in which acid vehicles were used. 
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The used EMD and amelogenin concentrations were selected based on preliminary assays and/or 
previous studies. In the case of EMD, the selected concentrations are most likely well below the 
concentrations used clinically, since gel-like EMD is applied locally, whereas such gel application 
and high concentrations are not possible in cell cultures. This discrepancy between clinical and the 
study concentration causes bias, and the observed effects can be highly concentration depend. 
However, since clinical concentrations are higher than the used study concentrations, it is likely that 
the proteins and possible cytokines of EMD diffuse into the surrounding tissues in vivo, thus 
resulting in the study concentrations at some point near the EMD treated site.  
 
Also the selected TGF-β1 concentration (10 ng/ml) in microarrays is somewhat contradictory. The 
used concentration was selected to be biologically meaningful according to previous studies 
(Pääkkönen et al 2008), while it is unclear whether EMD contains TGF-β1 or not and in what 
concentration. However, the response of carcinoma cells to growth factors and to TGF-β1 can be 
variable depending on the concentration. Thus, the current microarray analysis can only prove that 
EMD cannot contain TGF-β1 at the concentration of 10 ng/ml, but other concentrations of TGF-β1 
in EMD are still possible which warrants further studies.  
 
In addition to TGF-β1 concentration, also the data analysis of microarray results had limitations. 
Due to the lack of more sophisticated statistical methods available in the used microarray analysis 
software, and in microarray analysis software in general, the statistical significance in gene 
expression between study and control groups were judged according to P-values instead of CIs, 
which were otherwise used in this study. Also the fold change (FC) of the genes between control 
and study groups was calculated, but all the statistically significant results were regarded as true 
observations with biological relevance. This may cause overstatements in the results since 
′statistically significantly′ differing genes can have only relatively small difference in fold change at 
which point the biological relevance of the observation may be questionable.  
 
The fourth sub-study aimed to systematically review the existing studies focusing on the effects of 
EMD on carcinogenesis-related factors in vitro. There were no previous studies directly focusing on 
the associations among oral carcinoma cells and EMD. Therefore, the aim of the study was met by 
including all in vitro studies relevant to carcinoma-related factors and behaviour of oral cells. With 
the chosen method, the study was able to present and summarise all available biological data 
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concerning the topic. However, at the same time, the inclusion/exclusion criteria had to be relatively 
imprecise and it did not thus completely meet the criteria of systematic reviews. First and foremost, 
the inclusion/exclusion of the studies was not done according to the methodological diversities of 
the reviewed studies. Thus, in the included studies, different experimental set-ups were used 
including different cell lines, assay designs, EMD concentrations, dissolvent of EMD, time points, 
and controls. However, the underlying biological mechanism, and thus the results of a study, may 
depend on the assay design. Therefore, the conclusions of the review must be made taking these 
limitations into account.  
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8 CONCLUSIONS  
 
This study aimed to find out the effects of proteolytic enzymes present in GCF on the degradation 
and functions of EMD. In addition, the objective was to find out whether EMD could induce 
carcinogenesis-related genes, proteins and cellular processes in vitro or in vivo. Furthermore, the 
study aimed to contribute to the understanding of the composition of EMD, which has been 
observed to contain mainly amelogenin and possibly TGF-β1. The results of this study led to the 
following conclusions:  
 
I. GCF containing various proteases degrades EMD. EMD degradation depends on the state of 
periodontal disease being stronger in all states of periodontal disease (gingivitis, chronic and 
acute periodontal) compared to a healthy state. MMPs are probably not responsible of the 
degradation of EMD.  
II. GCF can decrease EMD induced proliferation of periodontal ligament fibroblasts. Unlike 
EMD, also amelogenin decreases the migration of PLFs. Thus, the effect of EMD on the 
proliferation is likely to be mediated by other cytokines in it and not the amelogenin itself. 
III. TGF-β1 regulates more and mostly different genes than EMD. This suggests that TGF-β1 
cannot be present in EMD at the studied concentration, if present at all. 
IV. EMD can induce several factors closely related to carcinogenesis in gene, protein, cell and in 
vivo levels. EMD enhance the expression of MMP-10 and MMP-9 in gene level and the 
production of gelatinases MMP-2 and MMP-9 and MMP-10 by cultured carcinoma cells. 
EMD stimulates the migration and in vitro wound closure of carcinoma cells. Furthermore, 
EMD also promotes metastasis formation in athymic mice bearing human tongue carcinoma 
xenografts. These results show that EMD can regulate several different factors, not only in 
benign cells, but also in highly malignant oral carcinoma cells. These results may have clinical 
implications and warrant further studies.  
V. Review of the literature confirms that EMD can regulate the production of several cytokines 
related to carcinogenesis in benign and malignant cell lines, but the evidence is scarce and in 
part contrasting.  
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APPENDIX 
 
The 15 most enriched GO terms according to P-value by 6 h (A1/A2) of EMD and 6 h (B1/B2) and 
24 h (C1/C2) of TGF- β1 treatments of HSC-3 cells. Table shows the term, p-value and number of 
genes (N. G.) related to various terms. * correspond to terms, which were the same for EMD and 
TGF-β1 after 6 h of treatment.  “ correspond to terms, which were the same for 6 h and 24 h of 
TGF-β1 treatments. 
 
 
 
